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vABSTRACT
Most existing chemotherapeutics lack adequate specificity for transformed cells
and therefore have high rates of collateral damage to normal tissue.  Moreover, such
therapies often depend on p53 to induce cell death and are ineffective on the large
number of human cancers that have lost p53 function. The discovery of novel p53-
independent cancer therapies is therefore of significant interest. The Chicken Anemia
Virus protein Apoptin selectively induces apoptosis in transformed cells in a p53-
independent manner while leaving normal primary cells unaffected. This selectivity is
thought to be largely due to cell type-specific localization: in primary cells Apoptin is
cytoplasmic, whereas in transformed cells the protein localizes to the nucleus.  The basis
for this cell type-specific localization remains to be determined.  In this study, Apoptin is
revealed to be a nucleo-cytoplasmic shuttling protein whose localization is mediated by
an N-terminal nuclear export signal (NES) and a C-terminal nuclear localization signal
(NLS).  Both signals are required for cell type-specific localization, as Apoptin fragments
containing either the NES or NLS fail to localize differently between transformed and
primary cells.  Significantly, cell type-specific localization can be rescued in trans by co-
expression of the two separate fragments, which are able to interact through an Apoptin
multimerization domain.  Interestingly, this multimerization domain overlaps with the
NES suggesting that these two activities may be functionally coupled in cytoplasmic
retention in primary cell types.  Factors present in transformed cells induce localization of
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Apoptin to the nucleus where a biochemically distinct, more soluble form of the protein
exists.
Using affinity-purification and mass spectroscopy it was found that, specifically
in transformed cells, Apoptin is associated with APC1, a subunit of the anaphase-
promoting complex/cyclosome (APC/C).  The APC/C is required to establish a mitotic
cell-cycle checkpoint, and its inhibition results in G2/M arrest and apoptosis. Expression
of wild type Apoptin in transformed cells inhibits APC/C function and induces G2/M
arrest and apoptosis, whereas Apoptin mutants that are unable to associate with APC1
have no effect.  In p53 null cells, ablation of APC1 by RNA interference induces a G2/M
arrest and apoptosis analogous to that observed following Apoptin expression.
Furthermore, Apoptin was found to induce the formation of PML bodies and to recruit
APC/C subunits to these nuclear structures suggesting a mechanism involving
sequestration and subsequent inhibition of the APC/C.
Thus, the results of this study clarify Apoptin cell type-specific localization
behavior and explain the ability of Apoptin to induce apoptosis in transformed cells in the
absence of p53.  This study advances a newly emerging field of viral mechanisms of
apoptosis involving G2/M arrest and APC/C modulation.  The resultant p53-independent
apoptosis suggests that the APC/C may be an attractive target for the development of
anti-cancer drugs.
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CHAPTER I
GENERAL INTRODUCTION
21.1 Cancer.  Cancer is a disease of autonomous and uncontrolled cell proliferation
generally spawned from stepwise somatic mutations that first deregulate cell division
and/or block programmed cell death resulting in perilous increases in cell number.  These
cells, having a significant growth advantage over their normal surrounding counterparts,
will usually expand in number to form a clonal benign neoplasm that will not yet have the
capacity to spread.  Selection of additional somatic mutations, however, will impart these
cells with qualities necessary for further transformation and eventual progression to a
fully malignant cancer with invasive capability (see Figure 1.1 and (68) for review).
The development of effective cancer therapies depends upon the discovery of
agents that selectively destroy tumor cells with a low degree of collateral damage to their
normal counterparts. This requires that an agent be responsive to properties or activities
that discriminate between normal and transformed cells.  In this regard, early in vitro
studies were performed to characterize those features of transformed cells that are altered
from normal cells.  The general phenotypic qualities elucidated from these efforts are
characteristic hallmarks of all cancer cells and a more detailed understanding of these
properties will be important for the development of tumor-selective treatments (31, 157).
One hallmark that occurs temporally early in transformation involves cells
gaining the capacity for unlimited proliferation (121). Unlike normal cells, which will
senesce and/or die after a finite number of divisions, tumor cells become immortalized, in
general, through mutations that abolish replicative senescence and abrogate cellular
crisis.  As mentioned before, this often occurs during the initial steps of transformation
3and usually involves prevention of programmed cell death (PCD or apoptosis) and release
of cell cycle control (68).
Another feature common to transformed cells is the loss of growth inhibition upon
contact with neighboring cells (1, 78).  Part of normal organ function depends on the
establishment of tight boundaries between tissues and cell layers through the shutdown of
cell duplication upon contact with other cells.  The outgrowth of a tumor beyond normal
cell and tissue boundaries involves mutations that abolish this contact-based signaling
that would normally lead to growth inhibition.
Transformed cells also show loss or alteration of growth factor dependence (34).
Normally cells require a certain level of growth signals from the environment to advance
past the G0/G1 restriction point and enter the cell cycle.  Additionally, cells from different
tissue types will differ in their growth factor requirements, restricting their proliferation
to particular microenvironments within the body.  Selective pressure will drive the
transformed cells to mutate and survive in environments lacking the normal supply of
growth factors (54).  Metastasis, or separation from the primary tumor site and
establishment of residence elsewhere in the body, involves gross changes in growth
factor responsiveness for transformed cells.
Malignant cancers also possess the ability to grow in the absence of anchorage
(146).  Detachment from a growth surface normally results in anoikis, a specialized form
of apoptosis resulting from the lack of anchorage-related signaling (66).  Fully
transformed cells lack this signaling cascade and can readily grow in suspension.  Tumor
cells that break through tissue barriers are usually shed to the bloodstream by the millions
4per day.  Most of these cells will die by anoikis, however the rare cells that fail to respond
to death signaling will survive the journey to distal tissues and may form metastatic
lesions (10).  Additional alterations in transformed cells include abnormal or defective
differentiation, increased cell motility and gross morphological alterations in cell shape
and size (see (31) for review).
Advances made in genetic methodology have allowed for the identification and
characterization of the specific genetic aberrations that underlie many of the above
mentioned phenotypes in transformed cells.  These mutations affect one of two major
classes of cancer-related genes: oncogenes and tumor supressors, which are grouped
according to how they functionally contribute to transformation.  Oncogenes contribute to
neoplastic disease through premature, aberrant or constitutive activation.  Such a situation
can occur in various ways including increase in copy number via gene duplication,
alteration of regulation following chromosomal translocation, or mutation of various
regulatory areas (e.g. promoter or silencer elements) that affect protein activation (see
(175) for review).
The erbB proto-oncogene (oncogene precursor prior to mutation) for example,
which encodes the cell surface receptor for epidermal growth factor (EGF), is normally
involved in extracellular signaling responses to mitogenic stimulus (56).  Receptor
ligation and activation by EGF results in phosphorylation-based signaling cascades
within the cell and activation of events including progression of the cell cycle and
metabolic stimulation (168).  Various mutations of erbB can result in constitutive
activation of receptor-tyrosine kinase activity and subsequent intracellular signaling
5independent of EGF ligand binding (24).  The resultant constancy in proliferative
signaling has been shown to contribute directly to several phenotypic hallmarks including
cellular immortilization (via recovery from crisis) as well as the obvious growth factor
independence of these cancers.  Similar oncogenic effects have been observed for other
closely related ErbB family members and many additional proteins of the greater
receptor-tyrosine kinase family (94).
The second class of cancer-related genes is the tumor suppressors.   Unlike
oncogenes, it is the mutational ablation of these genes that contributes to cell
transformation.  Normally these genes function in various situations to prevent
transformation and tumorigenesis and the loss of such genes results in the lack of this
protective effect. Moreover, unlike oncogenes the dysfunction of tumor suppressors is
functionally recessive and both maternal and paternal copies of the gene must be mutated
to fully contribute to transformation.  In most cases one allele is lost through gross
mutation (such as deletion of large chromosomal regions) and only in extremely rare
instances are both alleles inactivated by point mutation (see (185) for review).  The
discovery and functional characterization of tumor suppressors has proven more difficult
than for oncogenes due mainly to their recessive nature as well as difficulties inherent to
the isolation of genes based on loss of function.  The first characterized, and most well
understood tumor supressors to date, are the pRb and p53 proteins. Initially identified by
inherited susceptibility to retinoblastoma, the pRb protein functions as a veritable
gatekeeper for the cell cycle and blocks S phase induction by binding the E2F family of
transcription factors.  In its hypo-phosphorylated state, pRb remains tightly bound to E2F
6preventing gene transactivation.  Upon phosphorylation by cyclin E/Cdk2 complex in late
G1, pRb releases E2F resulting in nuclear translocation and subsequent activation of
genes critical for the induction and maintenance of S phase (Figure 1.2).  These include a
number of genes necessary for DNA replication including those encoding DNA
polymerase, dihydrofoate reductase and thymidine kinase (70).
Key to the commitment to begin the cell cycle is the ability to actively monitor
the fidelity of the genomic DNA throughout this process.  If mistakes occur, pRb must
again sequester E2F to block further entries into the cell cycle until the problem can be
addressed by repair machinery, thereby avoiding propagation of harmful mutations to the
daughter cells.  Cellular response to stress and DNA damage in S phase and throughout
the cell cycle relies on activation of p53. The p53 protein functions as a transcription
factor and serves to activate a great many genes involved in regulation of the cell cycle
and induction of apoptosis (63).  If the integrity of the DNA is compromised, cellular
levels of p53 rise through separation from MDM2, a negative regulator that constitutively
binds p53 and induces its degradation.  One well-characterized target of p53
transactivation is p21Waf1/Cip1, which actively silences the Cdk2-dependent
phosphorylation of pRb resulting in E2F sequestration and halt of S phase gene
expression (Figure 1.2).  The p21Waf1/Cip1 protein falls into a special class of cell cycle
regulators known as cyclin-dependent kinase inhibitors (CKI), a recently recognized class
of tumor suppressor proteins often found to be mutated in human cancers (100, 144).  If
damaging conditions persist or repair efforts fail, p53 can activate the transcription of
7various pro-apoptotic proteins (e.g. PUMA and NOXA) and sacrifice the cell entirely; a
choice that mechanistically remains poorly understood.
Together, pRb and p53 provide a nodal connection between those processes that
govern the entry and progression of the cell cycle and those that control apoptosis; two
related and interconnected pathways effecting the rate and multiplicity of cell duplication.
It is not surprising then to find that greater than half of all human cancers harbor
mutations in these genes (64, 155).  Moreover, it is theorized that those cancers that do
not present p53 and pRb mutations have likely still lost function of these proteins via
disruption of upstream regulators including CKIs (175). Specifically, these proteins
regulate two major cell cycle checkpoint mechanisms that monitor the G1/S phase
transition and the global cellular response to DNA damage and stress throughout the cell
cycle (12, 77).  The loss of cell cycle control and apoptosis resulting from the dysfunction
of these tumor suppressors often occurs early and constitutes the source of initial
proliferative phenotypes observed during transformation.
1.2 Treatment of cancer. Current therapeutic strategies for cancer remain dependent on
relatively crude methods of treatment usually involving surgery to remove cancerous
tissue, followed by radiation and/or chemotherapy aimed toward destruction of remaining
cancer cells.  Late stage, highly metastatic cancers with poor prognosis are usually treated
without surgery and rely on large doses of chemotherapeutics that lack sufficient
specificity for transformed cells.  Most broad-spectrum chemotherapeutic agents act to
inhibit features of cellular function and division common to all cells but are used at
8particular doses where transformed cells are more susceptible.  For example, some
cytotoxic agents routinely used for chemotherapy are more deadly to transformed cells
due to inherent higher rates of division.  This narrow therapeutic index results in
collateral effects on normal cells that also divide rapidly, such as loss of stomach and
intestinal epithelium, hair loss, and immunosuppresion (149).  Additionally, alkylating
agents, antimetabolites, and antibiotics including Adriamycin are among the most
commonly used drugs, all of which rely on p53 function to commit cells to apoptosis
(162).   For this reason, the large number of human cancers that have lost p53 function
are refractory to treatment with any of these agents.  Clearly there is a need for more
transformed cell-specific treatments that do not rely on p53 function to induce
programmed cell death.
Certain studies have achieved therapeutic successes by developing drugs that will
specifically inactivate well-characterized targets present only in transformed cells.  A
recent example of this target-based approach involved the design of a small molecule
inhibitor of the oncogenic fusion protein BCR-ABL, the causative agent of chronic
myeloid leukemia (CML).  This oncogene results from a reciprocal chromosomal
translocation (t(9;Ph22)) and fusion of the coding regions of the bcr and abl genes (see
Figure 1.3a and b).  The oncogenicity of the resultant fusion protein involves constitutive
activation of the Abl tyrosine kinase conferred by Bcr dimerization activity (see (11) for
review). In the early 1990s, a project was started to synthesize a small molecule inhibitor
that would act as a highly specific competitive inhibitor of ATP occupancy for the Abl
kinase.  The most promising compound to emerge from the screen, imatinib mensylate
9(STI571 Gleevec), showed exceptional specificity and potency in inactivating the Abl
kinase (Figure 1.3c-d) (120). With negligible toxicity, this compound was able to induce
a complete hematological remission in all CML patients receiving over 300 mg/day (21,
52).  Not surprisingly, the drug entered clinical trials and was quickly approved for use in
treating human CML.
Several factors contributed to success in the development of Gleevec, the most
prominent being the identification of a causative oncoprotein that was only present in
CML transformed cells.  This situation is relatively rare as most transformed cell
oncoproteins are present in normal cells as well, albeit at different levels and activities.
Thus, the fruitfulness of this approach for most cancers will depend on the elucidation of
novel transformed cell-specific activities that are sufficiently different or absent in
normal cells.  This, coupled with the specificity and low collateral toxicity inherent in
targeting particular molecular determinants, may produce promising agents with better
therapeutic efficacy in the treatment of a broad range of cancers.  In this regard, current
studies are using diverse strategies to identify novel factors and activities that might
discriminate between normal and transformed cells at the molecular level.
1.3 Utility of viruses in cancer research.  An increasing number of studies employ the
use of viruses or virus-encoded proteins to help unravel the complexities of cancer.
In general, viruses have evolved elegant and diverse strategies to manipulate many host
cell systems to facilitate their genome replication and protein expression, to abrogate host
defense mechanisms, and to facilitate viral egress.  Many of these strategies involve viral
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perturbation of the host cell genome and/or expression of viral proteins that affect the cell
cycle, cell signaling and apoptosis.  Thus, it is not surprising to find that many of these
viruses and viral proteins are also inherently oncogenic. Over 15% of worldwide cases of
human cancer have been etiologically linked to viral infection accounting for nearly 1.5
million cases per year (23).  A large number of studies are now focused on deciphering
the mechanics of these viruses and viral proteins and how they might help to unravel the
complexities of virus- and non-virus-related human neoplasia.
One pivotal example of viral influence on cancer research is the surprising
number of proto-oncogenes that were discovered through studies involving retroviruses
(23, 31, 186).  These RNA viruses integrate their genetic material into the host genome
during their life cycle and, as a latent pro-virus, are replicated as part of the normal host
cell genome.   During RNA genome production, retroviruses often extract host genomic
sequences via an imprecise transcriptional process that can result in packaging of
incomplete or mutated forms of cellular genes (Figure 1.4).  The insertion of these
sequences during subsequent infections can result in the expression of a viral oncogene,
usually under the control of relatively powerful LTR promoter elements.  Retroviruses
are also known to induce proto-oncogene activation by integrating directly into host open
reading frames (ORF) or through positional effects by integrating near a gene resulting in
aberrant LTR promoter transactivation.
Characterization of the first retroviral oncogene began in 1970 with pilot work by
Peter Duesberg and Peter Vogt during comparison studies of Avian Leukosis Virus
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(ALV) and its derivative Rous Sarcoma Virus1 (RSV) (53).  RSV was understood to be
an acutely transforming virus in chickens and was found to carry approximately 1.5kb of
additional genomic sequence beyond that of its parent ALV genome.  The oncogenicity
of RSV was attributed to this extra sequence as mutation or loss of this region ablated its
transforming capabilities (with no effect on virus replication) (98, 111).  The sequence
was eventually identified as a mutant form of the cellular src gene, the first characterized
protein-tyrosine kinase, which is involved in intracellular signaling in response to cell
surface receptor stimulation (20, 30).  The virally encoded src oncogene (v-src) is
truncated (as a result of imprecise retroviral gene capture) at the C-terminus where a
normally inhibitory phosphorylation takes place (Figure 1.5a) (25).  The lack of this site
results in a constitutively active Src protein and downstream effects including anchorage-
independent cell growth and mitogenic effects similar to that of ErbB dysfunction
previously discussed.  Thus, the study of RSV revealed the v-src gene, as well as its
cellular proto-oncogene counterpart, as a potent oncogene which is now known to be
relevant in human disease.
Continued focus on viral oncogenesis has elucidated many other viral and cellular
oncogenes.  For example, the oncogenic potential of the aforementioned EGF receptor
was first identified through studies involving avian erythroblastosis virus (AEV), which
carries an oncogenic form of erbB (57).  It was not until 1984, when the sequence of the
cellular EGF receptor gene was analyzed, that the true identity of v-erbB was revealed
(50, 154).  Interestingly, the v-erbB mutant from AEV lacks the extracellular ligand
1 RSV, the first clearly characterized and accepted tumor virus, was named for Peyton Rous, who isolated
and characterized the virus from a chicken tumor in 1911.
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binding domain of the receptor (Figure 1.5b), a truncation later shown to be the most
relevant mutation of this gene leading to constitutive activation in human cancers (31).
Studies of the Ableson Leukemia Virus in mice led to understanding of the oncogenic
potential of the Abelson kinase (v-abl) years before the role of the Bcr-Abl fusion in
CML was revealed (74, 108, 179).  Currently, over two-dozen oncogenes have been
characterized by study of retroviruses, all of which are relevant in human disease and are
potent inducers of neoplastic transformation (see Table 1.1).
Many endogenous viral proteins have been useful in the understanding of tumor-
specific processes as well.  The compact nature of viral genomes demands that the
limited number of proteins they produce exert a maximal effect on host cell function with
a minimal amount of protein interactions.  It is then understandable to find that many
viral proteins operate at nodal points of cellular protein interaction networks where a
single interaction can have vast downstream effects on cellular function.  These nodes
exist at critical regulatory areas where multiple cellular systems converge, many of which
are involved in the control and/or prevention of human malignancy. Thus, study of these
proteins has proven fruitful for elucidation and characterization of tumor suppressor
proteins as well, primarily because many of the same nodal regulators that oncogenic
viral products affect have been found to have functional relevance in non-virus related
human cancers.
One of the greatest advances in the understanding of tumor suppressors came in
the 1990s with the realization that virtually all DNA tumor viruses have convergently
evolved proteins that bind to and inactivate both pRB and p53 (Figure 1.6).  This curious
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observation seeded the understanding that both of these cellular proteins function as
seminal tumor suppressors whose dysfunction may be important, and possibly even
required, for cell transformation (175).  Examples of such viral proteins include
Adenovirus E1A and human papilloma virus (HPV) E7 which bind to pRb and inhibit
interaction with E2F.  Additional proteins from these same viruses target p53, namely
Adenovirus E1B55k and HPV E6.  The Simian Virus 40 (SV40) Large T protein is
uniquely able to bind to and inactivate both p53 and pRb regulators and is a potent viral
transforming agent (see (59) for review).  Many other DNA virus proteins have been
found to affect other tumor suppressors or have functions that indirectly effect p53 and
pRb (see Table 1.2).
In addition to elucidating proto-oncogenes and tumor suppresors, other molecular
aspects of oncogenesis have been clarified through viral study.  One such area involves
the viral suppression of apoptosis, a common and required event for cell transformation
and viral infection. One class of these viral products has evolved to specifically
counteract host defense mechanisms that induce apoptosis in response to infection.  Many
of these involve the host innate immune responses centered on cytokine production and
chemo-attraction of macrophages, neutrophils and NK cells that will induce apoptosis in
infected cells and clear resulting debris (152).  Many viruses produce proteins that block
signaling pathways involved in cytokine production and death receptor activation by use
of molecular mimicry.  Cowpox virus, for example, produces two protein products, CrmB
and CrmC, which traffic to the plasma membrane and competitively inhibit TNF ligand
association by mimicry of the TNF receptor extracellular domain (79).  Similarly,
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proteins such as Epstein-Barr Virus LMP-1 counteract death signaling by artificial
activation of NF-B pro-survival pathways using a TRAF receptor mimic (48).
Other viruses produce proteins that interfere more directly with downstream and
intrinsic apoptotic machinery.  Many of these involve mimicry of a class of cellular
proteins called cIAPs (cellular inhibitor of apoptosis) which normally function to either
bind and block activated caspases or to prevent activation of procaspases in response to
survival signaling (152).  Many baculoviruses encode vIAPs, viral mimics of cIAPs,
which block the action of particular subsets of caspases.  Notably, the discovery of cIAPs
and their role in apoptosis was elucidated through study of their viral counterparts (72,
105).
Interestingly, just as many early viral life cycle events require inhibition of
apoptosis, certain late events are propagated by the timed induction of apoptosis.  For
example, viruses may trigger cell suicide towards the end of the life cycle as a method of
viral egress.  Such a mechanism has certain advantages including the virions being
packaged into apoptotic bodies that are not only protected from inactivation by host
antibody responses but are also taken up by phagocytic cells allowing efficient spread of
infection.  This strategy is most useful to those viruses that have not evolved complex
mechanisms to evade host cell responses or anti-apoptotic factors (152).  Some viruses
will achieve successful infection cycles through both inhibition and induction of
apoptosis by using combinations of viral proteins, the effectiveness of which requires
precise timing and expression levels of these protein products.   Numerous proteins
including Adenovirus E1A and Hepatitis-B Virus HBx induce apoptosis in host cells and
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are critical for viral replication competency (107, 163). Of particular note are those viral
products that have been found to induce apoptosis independently of p53 activation
through actions at the mitotic checkpoint (73, 194).  Such viral proteins including
Adenovirus E4orf4, HIV-1 Vpr, and HTLV-1 Tax are currently being studied to clarify
as yet unclear apoptosis mechanisms from this checkpoint.
The mitotic checkpoint system exists to ensure proper segregation of genetic
material to each daughter cell during the late stages of mitosis (reviewed in (134)). The
timing of sister chromatid separation is tightly controlled to prevent onset of anaphase
until all chromosomes have achieved bipolar spindle attachment and possess adequate
spindle tension to align at the metaphase plate.  The sensory mechanism involved
provides a negative signal from kinetochores that lack spindle attachment to the aptly
named anaphase-promoting complex/cyclosome (APC/C), one of the major cellular E3
ubiquitin ligases involved in cyclin turnover (15).  The Mad and Bub family of proteins
actively associate with and inhibit the mitotic APC/C activator protein cdc20 resulting in
delay of onset of anaphase ((165) and revewed in (134)).  Once all sister chromatids have
achieved spindle attachment, Mad/Bub signaling ceases and cdc20 can activate APC/C
(APC/Ccdc20) resulting in the ubiquitination and subsequent destruction of mitotic cyclins
as well as securin, the inhibitory subunit of the separase enzyme.  Upon activation,
separase catalyzes the destruction of cohesin complexes that bind sister chromatids
together allowing for separation and migration of chromatin toward opposite spindle
poles (Figure 1.7).  A single unattached kinetochore can sufficiently activate the spindle
checkpoint and inhibit all APC/C function, stabilizing securin and preventing sister
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chromatid separation (147). Interestingly, it is now becoming evident that viral products
produced by many previously mentioned viruses (e.g. HTLV-1 and Adenovirus)
modulate various aspects of APC/C function (194).   This emerging field is beginning to
describe the mechanics of a novel pathway of virus-mediated G2/M cell cycle arrest and
programmed cell death that will be discussed later and may be of great interest in cancer
research.
1.4 Viral oncotropism and tumor cell-selective capacities. Observations made as early
as the 1920s indicated that some viruses might have specific replicative capacities in
transformed cells.  Subsequent studies of viral oncotropism has revealed that a surprising
number of naturally occurring viruses possess tumor-selective capabilities (19, 148).
Examples include parvoviruses, human reovirus and vesicular stomatitis virus (VSV), all
of which have been shown to replicate more efficiently in transformed cells (9, 60, 71,
190).  The underlying molecular mechanisms for such cancer cell selectivity are only
now being elucidated.  For example, Parvoviruses, which are excluded from infecting
normal quiescent cells because they lack the ability to forcibly induce S phase, seem to
take advantage of dysregulated S phase entry in transformed cells and replicate
vigorously (148).  Human reovirus adopts a more specific strategy relying on common
transformed cell dysregulation of the Ras pathway, which studies suggest relieves a block
in viral gene translation allowing replication and lysis to proceed (122).  Additionally,
some viruses with natural oncolytic ability have been either directly genetically altered or
adapted by serial passage through transformed cell culture to become more oncotropic.
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Adaptation of Newcastle disease virus (NDV) is a classic example of this approach.
Serial passage through various tumor cell cultures including human melanoma cell lines
has resulted in NDV strains with greater selectivity and replicative vigor in transformed
cells that may be of use in the direct treatment of cancer through solid tumor injection
(26, 27).
In addition to those viruses that have oncotropic and oncolytic activity, other viral
protein products have been found to have dramatic and selective transformed cell
activities apart from their parent viruses.  Molecular dissection and separate expression of
these proteins has only recently yielded interesting insights into tumor cell-specific
physiology that may prove useful for the development of future targeted drug therapies.
One such protein, chicken anemia virus (CAV) VP3, has such activity and will be the
focus of the research and discussion presented herein.
1.5 Chicken Anemia Virus (CAV). CAV was originally isolated and characterized in
1979 from an unusual subpopulation of chickens infected with Marek’s disease virus
(MDV).  MDV, a transforming herpesvirus, normally progresses with low mortality in
chickens mostly due to widespread vaccination, however a subpopulation of chickens
displayed rapid mortality and lack of effective immune response to MDV.  Upon close
inspection it was determined that these chickens were doubly infected with MDV and
another uncharacterized virus, CAV.  Subsequent inoculation of CAV alone in young
chickens resulted in severe anemia due to loss of erythroblastoid cells in the bone
marrow, subcutaneous and intramuscular hemorrhaging, and depletion of lymphoid
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organs (including thymocytes), which might explain the loss of protective immunity
observed with vaccinated adult chickens (2, 192).   Cytological analysis of CAV infected
tissues in these chickens indicated that losses of erythroblastoid cells and thymocytes was
due to large-scale induction of apoptosis in these populations (51).  CAV was later
isolated and characterized as being non-enveloped and icosahedral, with a rare circular
single-stranded DNA genome of approximately 2.3 Kbp (112, 113, 124).  These
properties placed CAV in a novel taxonomic class as the only member of the family
Circoviridae, genus Gyroviridae.
The CAV genome contains only 3 functional open reading frames (Figure 1.8a),
all of which are translated from a single polycistronic and polyadenylated transcript
controlled by promoter and enhancer elements upstream of the transcription start site (89,
124, 125, 137).  This promoter region contains at least 4 near-perfect 12bp repeat
elements that are able to recruit cellular SP1 and SP1-like transcription factors, a situation
not uncommon with other viral promoter elements (129).  Mutational studies indicate that
VP1 (51.6kDa), VP2 (24.0kDa) and VP3 (13.6kDa) proteins encoded by CAV are
required for the virus infectious life cycle (127, 128).  Limited study of VP1 has
demonstrated this protein to be largely structural and comprise the major protein
component of the virus capsule (127).  The VP2 and VP3 proteins are non-structural and
have been studied in greater depth in recent years.  Detailed studies involving VP2 have
demonstrated a dual-specificity phosphatase activity for this protein, a relatively rare
activity for viruses of this type.  Mutagenesis of the VP2 coding sequence reveals that
catalytic cysteines (C95 and C97) are able to coordinate the removal of phosphate groups
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from both tyrosine and serine/threonine residues and that these activities are necessary for
high titer replication of the virus (135, 136).   Authors of these studies speculate that VP2
activity may interfere with signaling pathways involved in host cell defense responses,
however little information is available to make any substantial conclusions.
1.6 CAV VP3 (Apoptin). The vast majority of research studies on CAV have focused
on the product of the third ORF for several reasons.  Immunohistochemical staining of
CAV infected tissues revealed that VP3 protein was found in the nucleus and, at later
timepoints, showed this protein to aggregate in large clusters concurrent with onset of
apoptosis.  Cloning and recombinant expression of VP3 in chicken lymphoblastoid T-
cells revealed that the activity of this protein alone results in apoptosis similar to that
induced by CAV (123, 126).   Intriguing results from subsequent studies reported that
expression of VP3 in numerous primary and transformed cell lines resulted in apoptosis
only in transformed cell types.  By contrast VP3 was functionally inert following
transient or long-term expression in various primary, normal cell types (37).
Remarkably, induction of apoptosis occurred in transformed cell types lacking functional
p53 suggesting a novel pathway to apoptosis of nuclear origin (37, 38, 198).  This
reproducible transformed cell-specific apoptosis makes VP3 an ideal candidate for the
study of cancer cell-specific physiology and the potential discovery of novel and p53-
independent cancer treatments.
The mechanism of transformed cell selectivity by VP3, henceforth deemed
“Apoptin” (126), is unknown.  Analysis of the 121 amino acid primary structure of
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Apoptin indicates no structural motifs or homology to any known proteins.  Sequence
analysis reveals a single putative nuclear export signal (NES) in a hydrophobic patch near
the N-terminus (a.a. 37 to 46) and basic residues at the C-terminus that may function in
nuclear import (Figure 1.8b).  Interestingly, Apoptin activity appears to be dependent on
sub-cellular localization; in primary normal cell types Apoptin is cytoplasmic whereas in
transformed cells it is nuclear (37, 119, 126, 196-198).  Preliminary mutagenesis
experiments have shown that abrogation of Apoptin nuclear localization either by
truncation of C-terminal sequences or by targeted mislocalization to alternate cellular
compartments results in a loss of killing capacity in transformed cell types suggesting
that nuclear localization is required for induction of apoptosis (42, 67, 126, 196).
Surprisingly however, forced expression of Apoptin to the nucleus of primary cell types
does not result in apoptosis indicating this is not sufficient for the Apoptin killing activity
and that additional activities are necessary for Apoptin activation (67).  Co-expression of
Apoptin with SV40-LT has been shown to confer nuclear localization and killing
capacity to Apoptin in primary cell types suggesting that particular elements in the
transformation process may be linked to Apoptin trafficking and activation (37, 130).
Analysis of recombinant in vitro purified Apoptin by circular dichroism reveals
no extensive -helix or -sheet motifs yet spectroscopic and electron microscopic
analysis suggests that Apoptin exists in large globular clusters that appear to be stable and
repeated in conformation.   Such clusters of an estimated 30-40 Apoptin monomers will
associate into larger, hydrophobic aggregates by virtue of sequences at the N-terminus of
the protein.  Gross truncations of the N-terminus of Apoptin results in a loss of all
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aggregation activity using recombinant protein (101, 102). Aggregation could play a role
in regulating sub-cellular localization patterns between primary and transformed cells as
Apoptin appears to form punctate structures in the cytoplasm of primary cells as opposed
to the nucleus of transformed cells where at similar time points it is diffuse (37).
Contributing factors to Apoptin cell type-specific localization are intriguing as such
activities are likely to be specific to transformed cells and worthy of future study.
Previously, Apoptin was reported to be phosphorylated by an as yet unidentified kinase
activity present in transformed cells.  Threonine 108 in the C-terminus of Apoptin was
shown to be phosphorylated and it is suggested that this event may serve to activate
nuclear entry and induction of apoptosis in transformed cells (151).  These findings have
proven to be controversial as several subsequent studies have either not successfully
reproduced phosphorylation of this residue or found no consequence in mutation of it (67,
176).  Despite research focused on elucidating such transformed cell-specific kinase
activity, the consequences of Apoptin phosphorylation and the nature of its activation are
quite unclear (see Appendix).
It is evident that cell death induced by Apoptin in transformed cell types occurs
by apoptosis.  Early studies reported that expression of Apoptin resulted in changes in
nuclear morphology including chomatin condensation, DNA fragmentation and nuclear
blebbing as well as other general features of apoptosis including presence of phosphatidyl
serine in the outer leaflet of the plasma membrane (37, 126, 138).  More recent analyses
of Apoptin-induced cell death have focused on clarifying the involvement of specific
apoptotic pathways.  Stimulation of apoptosis can be divided into two major types:
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intrinsic and extrinsic signaling.  The extrinsic pathway is activated by stimuli originating
outside the cell, usually in the form of cell surface receptor engagement.  Specialized
death receptors at the plasma membrane (e.g. TNF and Fas receptors) are engaged by
cognate ligands which are either in solution or membrane bound (e.g. cytotoxic T-
lymphocytes (CTL)).  Death receptor activation results in a “suicide signal” and the
recruitment of adaptor proteins that initiate caspase activation (reviewed in (85)).
Various studies involving either co-localization or yeast 2-hybrid screening have shown
Apoptin association with FADD (Fas Associating protein with Death Domain), Bcl-10,
DEDAF (death effector domain-associated factor) and Hippi (Huntingtin-interacting
protein-1 protein interactor), all of which are primary or secondary effectors of the
extrinsic apoptosis pathway (29, 40, 67).   However, functional support for such
associations is lacking and subsequent analysis of Apoptin derived cell death has revealed
signaling independent of any death receptor pathways.  Specifically, Apoptin induced cell
death occurs regardless of the status of FADD and caspase 8, key components of the
death-inducing signaling complex (DISC) involved in death receptor ligation and
activation (109).
More convincingly, Apoptin has been shown to stimulate intrinsic pathways to
apoptosis.  This type of programmed cell death involves interplay between various
members of the BCL-2-related family of proteins, which constitute the bulk of intrinsic
apoptotic circuitry for both pro- and anti-apoptotic signaling.  When expressed, BCL-2
itself is a potent inhibitor of many resident pro-apoptotic proteins of the same family and
generally functions to preserve the integrity of the mitochondria, the hub for modulation
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of intrinsic apoptosis (199).  Activation from internal stimulus induces various BCL-2-
related pro-apoptotic proteins such as BID, BIM, NOXA and PUMA to translocate to the
mitochondria and counter the action of BCL-2 (and similar anti-apoptotic proteins),
causing a dramatic loss of membrane integrity.  Cytochrome-c liberated from the
mitochondrial inner membrane will associate with and activate the adaptor protein Apaf-
1, which in turn activates procaspase 9.  These factors in complex with each other (a
structure called the apoptosome) cleave and activate various downstream effector
caspases (reviewed in (28, 65)).   Consistent with intrinsic activation, over-expression of
pro-survival factors such as BCL-2 and BCL-XL has been shown to block Apoptin
induced cell death (22), contrary to earlier less convincing evidence which suggested
otherwise (38, 41).  Additionally, downstream events following Apoptin expression
include the loss of mitochondrial membrane integrity and release of cytochrome-c,
followed by apoptosome formation, and effector caspase activation (22).
Cell death brought upon by Apoptin has at least been shown to be dependent on
the downstream activation of effector caspase 3.  Apoptin expression has been shown to
induce the processing of pro-caspase 3 and broad-spectrum inhibition of caspases using
the peptide inhibitor zVAD-fmk, which blocks activation of caspase 3, negatively affects
Apoptin-induced programmed cell death (PCD) (22, 39).  Thus, Apoptin expression in
transformed cell types results in death by virtue of intrinsic apoptosis components,
however the specific nuclear mechanisms of initiation remain unclear.
Preliminary experiments have been conducted to evaluate the therapeutic
potential of direct Apoptin gene transfer into human tumor cells in vitro as well as solid
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human tumors in vivo via different viral vector systems.  Success has been achieved in
the selective killing of tumor cells in both cases by using adenoviral vectors for Apoptin
transgenesis.  Apoptin treatment of xenografted human hepatomas in nude mice by direct
tumor injection has been shown to decrease mean tumor volumes between 75 and 100
percent with little collateral damage to surrounding tissues (139, 169).   Other studies
have had similar successes by coupling Apoptin expression to delivery through
autonomous oncotropic and oncolytic viral vectors, such as rodent parvovirus, thereby
increasing tumor cell selectivity at even higher viral titers conducive to in vivo therapy
(32, 117, 131, 158).
Apoptin may have greater value beyond its uses for direct tumor therapy.  Studies
focusing on the mechanics of Apoptin tumor selectivity are likely to produce novel
transformed cell-specific protein activities or molecular targets worthy of further study.
Activities coupled to Apoptin cell-specific localization and/or apoptosis could be
exploited for targeted drug therapies similar to STI571, but useful for a broad spectrum of
cancers.  Of particular significance is the apparent lack of dependence on p53
functionality for Apoptin-induced PCD.  As mentioned before, the p53 tumor suppressor
regulates the major nuclear pathway to apoptosis in response to many cellular stresses
and would ordinarily be a likely candidate for Apoptin death signaling.  However,
apoptosis occurs in those transformed cell types that lack p53 function equally as well as
those that do not suggesting an alternate or downstream mechanism of initiation.  Clearly
the study of Apoptin and other novel pathways to apoptosis that do not rely on p53 are of
great therapeutic interest.
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The following studies focus on clarification of both the tumor cell selectivity of
Apoptin as well as identification of novel targets and pathways involved in the induction
of apoptosis by Apoptin in transformed cell types in the absence of functional p53.  Many
advances have been gained in the understanding of Apoptin structure and function
through the research that follows.  Of note are also the insights that have been gained
spanning to areas involving the cell cycle and cancer biology.
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Figure 1.1. Stepwise mutations leading to cancer. The process of normal cell
transformation involves the stepwise accumulation of somatic mutations, each affecting a
particular gene. Initiating mutations usually involve deregulation of the cell cycle and/or
suppression of apoptosis leading to abnormally excessive cell growth, or hyperplasia.
Subsequent mutations in other genes result in the acquisition of common cancer cell
phenotypes (hallmark abilities) that together will contribute to invasive metastatic
disease.
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(early premalignant)
Tertiary mutation
(late premalignant)
Quaternary mutation
(invasive metastatic)
normal cell
Figure 1.1
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Figure 1.2. pRb and p53 tumor suppressor functions. Together, pRb and p53 regulate
major mechanisms controlling the rate and multiplicity of cell duplication. The pRb
protein, which normally inhibits the function of the E2F family of transcription factors, is
phosphorylated following increases in G1 cyclin-Cdk activity. Cyclin D/E-Cdk
complexes hyperphosphorylate pRb resulting in a release of E2F, which transactivates
many genes involved in the progression and maintenance of S-phase. During DNA
synthesis and throughout the cell cycle, if damage or mistakes occur, p53 protein levels
rise and initiate a host of responses. One of these responses involves transactivation and
expression of p21, a cyclin-dependent kinase inhibitor (CKI) that blocks the activity of
various cyclin-Cdk complexes including Cdk1 and Cdk2. This blocks advance of the cell
cycle at several points including S-phase initiation. Cdk2 phosphorylation of pRb is
inhibited causing E2F sequestration and S-phase gene shutdown. Together, these tumor
suppressors provide a plexus where the initiation and progression of the cell cycle is
intimately connected to mechanisms that preserve the fidelity of these processes.
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Figure 1.3. Targeted inhibition of the Bcr-Abl oncoprotein. (A) Schematic diagram
of reciprocal translocation event (t(9;Philadelphia 22)) leading to fusion of the Bcr and
Abl coding regions. (B) Detail of the Bcr and Abl protein domain architecture.
Translocation between coding regions for these proteins results in truncation and fusion
of the N-terminal oligomerization region of the Bcr protein with the C-terminal tyrosine
kinase domain of Abl. Oligomerization of this fusion protein via Bcr sequences results in
autophosphorylation and constitutive activation of the Ableson kinase. (C) Crystal
structure of the Abl kinase (green) bound to the STI571 (Gleevec) inhibitor. Gleevec
(blue) associates directly with the catalytic binding pocket of the kinase and blocks entry
of ATP. (D) Chemical structure of Gleevec illustrating bonding patterns observed in the
Abl active site.  (Panels C and D from Nagar, B et al. 2002. Cancer Research. (120))
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Figure 1.4. Retroviral oncogene capture.
A hypothesized scheme depicting the steps involved in retroviral cellular gene capture
and oncogene production are shown. Proviral integration occurs in the host cell genome
frequently in proximity to a cellular genetic locus. Failure in termination during
transcription of the viral genome results in partial readthrough transcription of the cellular
locus and generation of hybrid virus/host pre-mRNA. Abnormal splicing events can lead
to fusion of the viral and host cell exons in the mature mRNA, which is then packaged
into virions with another normal copy of the viral genome. Recombination events take
place during reverse transcription in subsequent infectious cycles resulting in the stable
integration and expression of a hybrid provirus expressing mutated cellular genes under
the control of relatively powerful LTR promoter elements.
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Figure 1.5. Example retroviral oncogenes. (A) Comparison of the normal cellular Src
(c-Src) and viral oncogenic Src (v-Src) proteins. The Src protein has similar domain
architecture to that of the Abl protein. In this case, a normally inhibitory phosphorylation
site (Y-527) is deleted from v- Src version via truncation of C-terminal sequences as a
result of retroviral gene capture. This results in constitutive activation of Src kinase
activity and downstream effects that can contribute to transormation. (B) Comparison of
the normal cellular erbB (c-erbB/EGF receptor) and viral oncogenic erbB (v-erbB)
proteins. In the normal situation, erbB receptor activation occurs in response to EGF
ligand docking at the extracellular protein domain. The v-erbB protein lacks this domain
and is rendered ligand insensitive. Therefore, activation of this EGF receptor occurs
constitutively regardless of the presence or absence of EGF.
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Table 1.1. Retroviral Oncogenes. The study of retroviruses has elucidated over two-
dozen oncogenes. Each of these oncogenes originated from a cellular proto-oncogene
and as a result of retroviral gene capture, exists in a mutated form that has relevance in
transformation. The viral oncoprotein product is indicated as well as the hybrid protein
generated upon fusion with viral sequences. Also indicated is the species from which the
oncogene was originally liberated (owing to the tropism of the particular retrovirus).
Table 1.1 Retroviral Oncogenes
Oncogene Virus Species Oncoprotein
abl Abelson leukemia virus mouse p120gag-abl
akt AKT8 virus mouse p105gag-akt
cbl Cas NS-1 virus mouse p100gag-cbl
crk avian sarcoma virus CT10 chicken p47gag-crk
erbA avian erythroblastosis virus-ES4 chicken p75gag-erbA
erbB avian erythroblastosis virus-ES4 chicken p72gag-erbB
ets avian erythroblastosis virus-E26 chicken p135gag-myb-ets
fes Gardner-Arstein feline sarcoma virus cat p110gag-fes
fgr Gardner-Rasheed feline sarcoma virus cat p70gag-fgr
fms McDonough feline sarcoma virus cat p180gag-fms
fos FBJ murine ostogenic sarcoma virus mouse p55fos
fps Fujinami sarcoma virus chicken p140gag-fps
jun avian sarcoma virus 17 chicken p55gag-jun
kit Hardy-Zuckerman-4 feline sarcoma virus cat p80gag-kit
maf AS42 sarcoma virus chicken p100gag-maf
mos Moloney sarcoma virus mouse p37env-mos
mpl myeloproliferative leukemia virus mouse p31env-mpl
myb avian myeloblastosis virus chicken p45gag-myb-env
myc avian myelocytomatosis virus-29 chicken p110gag-myc
qin avian sarcoma virus 31 chicken p85gag-qin
raf 3611 murine sarcoma virus mouse p75gag-raf
avian carcinoma virus MH2 chicken p100gag-raf
rasH Harvey sarcoma virus rat p21rasH
Rasheed sarcoma virus rat p29gag-rasH
rasK Kirsten sarcoma virus rat p21rasK
rel reticuloendotheliosis virus turkey p56env-rel
ros UR2 sarcoma virus chicken p68gag-ros
sea avian erythroblastosis virus S13 chicken p137env-sea
sis simian sarcoma virus monkey p28env-sis
ski avian SK virus chicken p110gag-ski-gag
src Rous sarcoma virus chicken p60src
yes Y73 sarcoma virus chicken p90gag-yes
Cooper, G.M. 1995 Oncogenes.
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Figure 1.6.  Convergently evolved viral inhibitors of p53 and pRb.
The central role of p53 and pRb in cell cycle control and tumor suppression is illustrated
by the many convergently evolved DNA tumor virus proteins that bind and inhibit these
proteins.
Table 1.2. DNA tumor virus proteins and their activities. The study of DNA virus
proteins with transforming capability has resulted in the discovery of the many cellular
targets of these proteins that are important in cell cycle regulation and tumor suppression.
Examples of tumor virus proteins and their respective activities are shown. All of these
proteins have direct or indirect roles in the inhibition of major cellular tumor suppressors.
p53
pRB
SV40-LT
Ad-E1B55k
Ad-E1A
HPV-E7
EBV-EBNA-3C
HPV-E6
Table 1.2 DNA tumor virus proteins
Virus Protein Activities / Effects
Adenovirus E1A direct pRb inhibition
E1B-55K direct p53 inhibition
HPV E7 direct pRb inhibition
E6 direct p53 inhibition
HTLV-1 Tax transcriptional repression of p53, p18ink4c , p19ink4d
direct p15ink4b  and p16ink4a  inhibition
HBV HBx transcriptional repression of p21waf1/cip1
transcriptional activation of cyclins A and E
HCV NS3 transcriptional repression of p21waf1/cip1
mislocaliaztion of p53
NS5A modulation of p53 target transactivation
SV40 Large T direct inhibition of p53 and pRb
Small T direct inhibition of PP2A tumor suppressor 
Figure 1.6
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Figure 1.7. The mitotic checkpoint. Proper distribution of genetic material to each
daughter cell in mitosis is dependent on the precise timing of sister chromatid separation.
The anaphase-promoting complex/cyclosome (APC/C) serves as the central regulator of
this process in mitosis and functions in a negative regulatory system that prevents
progression of mitosis until all chromosomes have attached spindles and possess
adequate tension so as to align at the metaphase plate. Signaling is accomplished by the
Mad/Bub family of proteins, which continually relay from unattached kinetochore
complexes to bind and inactivate the APC/C activator protein Cdc20. Once all
kinetochores possess spindles, Mad/Bub signaling ceases and active APC/Ccdc20
ubiquitinates several targets including mitotic cyclins as well as securin, the inhibitory
subunit of the separase enzyme. Active separase then cleaves cohesin complexes that
bind sister chromatids together allowing for their rapid retraction to the spindle poles,
anaphase progression, and subsequent exit from mitosis.
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Figure 1.8. Chicken Anemia Virus (CAV). (A) Diagram of circular ssDNA genome of
CAV. Transcription is initiated from a single start site (354bp) downstream of a non-
coding region and produces a polycistronic, polyadenylated mRNA. Translation occurs
from alternate start codons to generate the three CAV proteins VP1, VP2, and VP3. The
coding region for VP3 is buried within that of VP2 and is translated from an alternate
reading frame. (B) Schematic of VP3 protein domains. Sequence analysis reveals a
putative nuclear export signal (NES) toward the N-terminus. Consensus sequence for
canonical NES is shown. Basic patches at the C-terminus may function in nuclear
import.
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CHAPTER II
CELL TYPE-SPECIFIC LOCALIZATION OF CAV APOPTIN IS REGULATED BY
MULTIFUNCTIONAL DOMAINS THAT CONTROL NUCLEO-CYTOPLASMIC
SHUTTLING
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Abstract
The Chicken Anemia Virus protein Apoptin selectively induces apoptosis in
transformed cells while leaving normal cells unaffected.  This selectivity is thought to be
largely due to cell type-specific localization: in primary cells Apoptin is cytoplasmic,
whereas in transformed cells the protein localizes to the nucleus.  The basis for this cell
type-specific localization remains to be determined.  In this study, Apoptin is revealed to
be a nucleo-cytoplasmic shuttling protein whose localization is mediated by an N-
terminal nuclear export signal (NES) and a C-terminal nuclear localization signal (NLS).
Both signals are required for cell type-specific localization, as Apoptin fragments
containing either the NES or NLS fail to localize differently between transformed and
primary cells.  Significantly, cell type-specific localization can be rescued in trans by co-
expression of the two separate fragments, which are able to interact through an Apoptin
multimerization domain.  Interestingly, this multimerization domain overlaps with the
NES suggesting that these two activities may be functionally coupled in cytoplasmic
retention in primary cell types.  Factors present in transformed cells induce localization of
Apoptin to the nucleus where a biochemically distinct, more soluble form of the protein
exists.  Previous reports have suggested that Apoptin phosphorylation at the C-terminus
may control localization activity as well as induction of apoptosis.  In contrast, this study
shows that this phosphorylation event and region of the protein were dispensable for the
achievement of cell type-specific localization and instead, the unique Apoptin NES
domain was found to confer this activity. These data suggest that nucleocytoplasmic
shuttling activity is necessary for proper Apoptin localization and apoptotic activity and
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suggest that biochemical differences conferred by the Apoptin N-terminus provide the
basis for cell type-specific localization between normal and transformed cells.  Based on
these results, a model is proposed for the differential localization of Apoptin between
normal and transformed cells.
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Introduction
Viruses employ diverse strategies to alter host cell functions and facilitate the
viral life cycle.  For this reason, many viral proteins target cellular pathways at critical
points, such that many cellular activities can be altered with a minimal amount of virus-
host factor interaction. For example, numerous DNA viruses are known to encode
proteins that target and inhibit p53 and pRB; two of the key growth regulators in
mammalian cells (see Chapter I, Figure 1.6)(93, 200).  Thus, the study of virus-host
interactions has been valuable in understanding a wide variety of cellular processes.  For
instance, apoptosis induced by viral proteins is a common mechanism to facilitate viral
egress and promote viral spreading.  Many animal viruses encode proteins that are potent
inducers of apoptosis and in certain cases such activity is selective to transformed cells.
One example is the Apoptin protein encoded by the Chicken Anemia Virus (CAV).
CAV exists as the only member of the family Circoviridae, genus Gyroviridae
and is the etiologic agent of chicken infectious anemia, which results from large-scale
apoptosis of cortical thymocytes and erythroblastoid cells in the bone marrow (84).  The
CAV genome encodes 3 proteins, the third of which (VP3 or Apoptin) was found to be
responsible for induction of apoptosis.  Two properties of CAV Apoptin make it a
provocative protein to study for cancer-specific processes.  First, Apoptin selectively
induces apoptosis in transformed cells while leaving primary normal cells intact and
unaffected (37).  Transient or long-term expression of Apoptin in primary cells has no
deleterious effects.  Second, induction of apoptosis in transformed cells occurs regardless
of the status of the p53 tumor suppressor (38). The p53 pathway is the major mechanism
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by which cancer cells are destroyed by chemotherapy and radiotherapy (162).  Over half
of all human tumors are mutated in the p53 gene rendering these cancer cells refractory to
such forms of therapy (155). Therefore, the study of Apoptin represents a system to study
novel p53-independent pathways to apoptosis in cancer cells and may also elucidate
cancer-specific processes.
The transformed cell-specific killing effects of apoptin are largely related to
differences in subcellular localization of the protein. In primary cells, Apoptin localizes
in the cytoplasm whereas in transformed cells, it is nuclear (37). This differential
localization of Apoptin is highly unique and the basis for this behavior is yet to be
determined.  The study of cellular mechanisms regulating this localization may provide
valuable insights into transformed cell physiology.  In the present study the basis of
Apoptin cell type-specific localization is addressed and a model for transformed cell-
selective killing is discussed.
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Materials and Methods
Cells and Adenoviruses.  Primary foreskin fibroblast (PFF), H1299 (from ATCC), and
HA1-IM cells (S. Bacchetti, McMaster University, Hamilton, Canada) were maintained
in Dulbecco’s Modified Eagle’s Medium (DMEM) supplemented with 10% FBS plus 10
mg/ml streptomycin and 10 U/ml penicillin (Sigma, St Louis, MO) at 37°C under 5%
CO2 (95% air). Apoptin adenovirus (Ad-Apwt) containing a single 5’ FLAG epitope was
generated using the AdEasy XL Adenoviral Vector System (Stratagene) according to the
manufacturer’s instructions.  Ad-Ap-pmNES was generated by site directed mutagenesis
of Apwt sequence as indicated followed by generation of FLAG epitope tagged
adenovirus as indicated above.  Viral supernatants were plaque purified, amplified, and
titers determined by plaque assay.  LacZ adenovirus (Ad-LacZ) was prepared as
previously described (8).  Cells were infected at approximately 80% confluence at an
MOI of 35.  Adenovirus was added to cells in a minimal volume of culture media and
gently agitated at 37°C under 5% CO2 for 1 h.  Following infection, culture media was
added and cells were incubated for indicated times.
Plasmid Constructions. GFP-Apoptin deletion mutants were constructed by PCR
amplification of Apoptin sub-sequences, which were directionally cloned into the vector
pEGFP-C1 (Clontech).  GFP-Ap-pmNES and -pmNLS were generated by PCR site-
directed mutagenesis.  GFP-Ap-SV40NLS was made by PCR amplification of Apoptin
amino acids 1-88 with simultaneous addition of SV40 LT NLS sequence (PKKKRKV) to
the C-terminus followed by cloning into pEGFP-C1.  DsRed-Apoptin fusions were
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generated by PCR amplification of GFP-Apoptin templates followed by cloning into
pDsRed1-N1 (Clontech, Palo Alto, CA).  For the dsRed-Ap(82-121) construct, a start
codon was added because the endogenous Apoptin 5’ sequence had been removed. GFP-
Ap-RevNES was generated by replacing the wild type Apoptin NES sequence with an
oligonucleotide linker containing the HIV-1 Rev NES.  To generate the dsRed-dnRan
fusion, a construct expressing dnRan (Dr. Lan Xu, University of Massachusetts Medical
School, Worcester, MA) was PCR amplified and cloned in-frame into pDsRed1-N1.  All
constructs were confirmed by restriction digest analysis and DNA sequencing.
Immunofluorescence and Fluorescence Microscopy.  Ad-Apwt-infected PFF and
HA1-IM cells were fixed in 4% paraformaldehyde (in PBS), permeablized in 0.5%
TritonX-100 (in PBS) and stained with -Flag M5 primary mAb (Sigma) followed by -
mouse Ig Texas Red-conjugated secondary Ab (Sigma).
For fluorescence microscopy, H1299 cells were transiently transfected using
Effectene reagent (Qiagen) and PFF transfections were performed using an Amaxa
Nucleofector (Amaxa Biosystems).  After 24 h, cells were fixed in 4% paraformaldehyde
and stained with DAPI.  Cells were mounted on slides and observed using a Ziess
Axiophot2 fluorescence microscope using Axiovision 4.2 software.
Nucleo-cytoplasmic Shuttling Assays. ~5 x 105 PFF cells were transiently transfected
with GFP-Apwt, and 24 h later treated with leptomycin B (LMB) at a final concentration
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of 2.5 ng/ml.  ~5 x 105 H1299 cells were transfected with GFP-Apwt or Rev-GFP, and 12
h later transfected with a construct expressing dsRed-dnRan.
Heterokaryon Assays. ~5 x 105 H1299 or PFF cells were transiently transfected with
dsRed-Apwt or GFP-Apwt, respectively, by Amaxa nucleofection.  Immediately
following transfection, cells were either mixed or plated separately (for controls) in 6
well format on cover slips and left to recover for 12 h.  Media was then removed and
cells were washed twice in PBS and fused by exposure to a solution of 50% PEG 1000 in
serum-free DMEM for 125 s at room temperature.  PEG solution was then removed by
washing with PBS and fresh medium was added.  After overnight recovery, cells were
fixed in 4% paraformaldehyde (in PBS) and stained with DAPI, and Apoptin localization
was determined by fluorescence microscopy.
Immunoprecipitations and Immunoblotting.  For multimerization experiments, ~1 x
107 H1299 cells were transiently transfected with GFP-Apoptin truncation mutants using
Effectene.  After 12 h cells were infected with Ad-Apwt and incubated for 24 h.  Cells
were harvested and lysed in Buffer X (50 mM Tris, pH 8.5, 250 mM NaCl, 1 mM EDTA,
1% NP40, Complete Mini tablet (Roche)) on ice for 20 min.  Cell debris was removed by
centrifugation and supernatants were incubated with 30 ml Ezview Red -Flag M2
affinity beads (Sigma) at 4°C for 4 h.  Beads were then washed in Buffer X and bound
proteins were eluted by boiling in SDS sample buffer.  For solubility analysis, ~1 x 107
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H1299 or PFF cells were infected with Ad-Apwt followed by incubation for 48 h.  Cells
were then harvested and immunoprecipitated as described above.
For immunoblotting, samples were resolved by 15% SDS-PAGE and transferred
to nitrocellulose.  Blots were blocked with 5% milk in TBS-T and probed with either -
Flag M2 mAb (Sigma) or -GFP mAb (Clontech) followed by appropriate HRP-
conjugated -Ig secondary Ab (Amersham Biosciences).  Protein bands were visualized
by chemiluminescence using SuperSignal Substrate (Pierce).
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Results
Apoptin is a Nucleo-cytoplasmic Shuttling Protein.   To optimize expression of
Apoptin for proteomic studies, an adenovirus expressing FLAG-tagged Apoptin (Ad-
Apwt) was constructed.  Apoptin expression was confirmed by immunoblot analysis (see
Chapter III).  Previous studies have shown that Apoptin is nuclear localized in
transformed cells and cytoplasmic in untransformed or primary cells (37).  To determine
the intracellular localization of Flag-tagged Apoptin, immunocytochemistry was
performed using an anti-FLAG monoclonal antibody.  Figure 2.1a shows that in primary
foreskin fibroblasts (PFFs) Apoptin stained with a characteristic cytoskeletal-like pattern
with nuclear exclusion, whereas in non-small cell lung carcinoma H1299 cells the protein
was completely nuclear. Thus, FLAG-tagged Apoptin exhibits the characteristic
differential localization in transformed and primary cells described previously (37).
These results also suggest that the protein may be associated with cytoskeletal
components or may a have filamentous structure in primary cells.
The ability of the CAV protein Apoptin to localize to either the nucleus or
cytoplasm depending on cell type suggested the protein may undergo nucleo-cytoplasmic
shuttling.  To determine whether Apoptin shuttles in primary cells, primary foreskin
fibroblasts (PFFs) were infected with Ad-Apwt virus and 24 hours later were treated with
leptomycin B (LMB), a compound that specifically blocks Crm1-mediated nuclear
export.  If Apoptin shuttles in primary cells, then blocking nuclear export should result in
the accumulation of Apoptin in the nucleus.  Figure 2.1b shows that LMB treatment
results in nuclear accumulation of Apoptin in PFF cells indicating that Crm1-dependent
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nucleo-cytoplasmic shuttling is taking place.  Interestingly, not all Apoptin protein was
engaged in shuttling and much remained cytoplasmic and aggregated suggesting that this
form of Apoptin may be stable or tightly associated with filamentous structures.  For
subsequent experiments, a plasmid was constructed with Apoptin fused to the C-terminus
of green fluorescent protein (GFP-Apwt).  To confirm shuttling behavior with this
construct, PFF cells were transiently transfected with GFP-Apwt and the cells were
treated with LMB as before.  Figure 2.1c shows that LMB treatment also resulted in
nuclear accumulation of GFP-Apwt in PFFs.  A larger shuttling pool of Apoptin was
found with GFP-Apwt following LMB treatment suggesting fusion of Apoptin with GFP
at the N-terminus may have some effect on cytoplasmic retention in PFF cells.
To test whether Apoptin also shuttles in transformed cells, an assay was
developed to monitor nucleo-cytoplasmic shuttling of a predominantly nuclear protein.  A
dominant-negative Ran GTPase mutant (dnRan), which blocks Ran-dependent nuclear
import (92), was expressed H1299 cells.  To validate this approach, a control experiment
was performed monitoring the effect of dnRan on localization of HIV Rev, a well-
characterized nucleo-cytoplasmic shuttling protein (87, 114, 115).  Figure 2.1d shows, as
expected, that a dsRed-dnRan fusion-protein localized to the nuclear periphery (87, 115)
and that a Rev-GFP fusion-protein accumulated in the nucleolus (171).  Co-expression of
dsRed-dnRan and Rev-GFP resulted in loss of nuclear GFP signal, confirming that Rev-
GFP exited the nucleus and was blocked for subsequent re-entry.  Similarly, expression
of dsRed-dnRan resulted in loss of nuclear GFP-Apwt, indicating that Apoptin shuttled in
transformed cells.  Collectively, the data of Figures 2.1.b-d indicate that Apoptin
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localization is regulated by nucleo-cytoplasmic shuttling in both primary and transformed
cells, and that nuclear import and export are mediated by common cellular trafficking
machinery.
Apoptin nuclear localization is mediated by a dominant transformed cell-specific
activity.  To determine whether the transformed or primary cell contained a dominant
Apoptin localization activity, a heterokaryon experiment was performed.  PFF cells were
transiently transfected with a plasmid expressing GFP-Apwt, and H1299 cells were
transiently transfected with a plasmid expressing Apoptin fused to the C-terminus of
dsRed (dsRed-Apwt).  Twelve hours later cells were combined, fused with polyethylene
glycol, and allowed to recover overnight.  Figure 2.2a shows that when either PFF/GFP-
Apwt or H1299/dsRed-Apwt cells were self-fused, the expected localization patterns
were observed.  However, fusion of PFF/GFP-Apwt cells with H1299/dsRed-Apwt cells
resulted in the translocation of PFF-derived GFP-Apwt to the nucleus where it co-
localized with dsRed-Apwt.  These results indicate that transformed cells contain a
dominant activity that confers Apoptin nuclear localization.
Localization of Apoptin was also monitored in HA-1 cells, a clonal population of
human embryonic kidney cells transformed with SV40 early region DNA that bypass
senescence and enter crisis (33).  HA-1 cells were infected with Ad-Apwt and
localization was monitored both before (passage 44) and after (passage 94) crisis.  Figure
2.2b shows that Apoptin exhibited a filamentous, cytoskeletal-like cytoplasmic staining
pattern in pre-crisis cells, whereas in post-crisis cells Apoptin localized predominantly to
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the nucleus.  Thus, the dominant activity in transformed cells that directs Apoptin to the
nucleus appears early during the transformation process.
Biochemical properties of Apoptin differ between primary and transformed cells.
Others have previously reported that Apoptin forms large aggregates in primary cells
(37).  One hypothesis is that this aggregation may reflect a fundamental difference in the
biochemical state of Apoptin in primary versus transformed cells.  The
immunoprecipitation experiment of Figure 2.2c shows that Apoptin was highly resistant
to extraction from PFFs compared to H1299 cells in low ionic strength buffer.  In fact, in
primary cells the majority of Apoptin was not solubilized even under high ionic strength
conditions (data not shown).  Based upon the filamentous, cytoplasmic staining pattern
observed in primary cells (see Figures 2.1a and 2.2b), Apoptin may be tightly associated
with the cytoskeleton, which could explain the difference in solubility between primary
and transformed cells.  It is also possible that this solubility difference is related to
Apoptin sub-cellular localization.  For example, Apoptin may be generally insoluble in
the cytoplasm but soluble in the nucleus.  To test this possibility, PFF cells infected with
Ad-Apwt were treated with LMB and subjected to immunoprecipitation as before.
Figure 2.2d shows that LMB treatment had no effect on the degree of extraction
indicating that forcing Apoptin to the nucleus of a primary cell is not sufficient to
increase solublility.
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Functional characterization of Apoptin NES and NLS sequences.  Experiments were
performed to characterize the specific sequence elements that contribute to nucleo-
cytoplasmic shuttling.  Previous studies have noted a putative NES comprising amino
acids 37-46 in the N-terminus and a putative NLS comprising residues 70-121 in the C-
terminus (shown in Figure 1.8b, Chapter I) (42, 176).  To determine whether the putative
N-terminal sequence was a functional NES, a mutant was constructed in which the core
residues leucine-44 and leucine-46 were mutated to alanine (GFP-Ap-pmNES).  Figure
2.3 shows that in PFFs GFP-Ap-pmNES mislocalized to the nucleus, indicating that the
putative Apoptin NES is functional and that the NES activity of Apoptin is required for
cytoplasmic accumulation in primary cells.  The putative bipartite NLS contains two
domains highly enriched in lysine and arginine (residues 86-88 and 116-118). An NLS
mutant was constructed in which both trios of basic amino acids were mutated to alanine
(Ap-pmNLS).  This mutant mislocalized to the cytoplasm in H1299 cells, indicating the
NLS is required for nuclear localization.  Thus, Apoptin contains both a functional NES
and NLS, consistent with the nucleo-cytoplasmic shuttling activity described above.
Apoptin fragments containing either the NES or NLS fail to undergo cell type-
specific localization.  The simplest explanation for the differential localization of
Apoptin in primary and transformed cells is that one of the localization signals is subject
to cell type-specific regulation.  For example, the NES might be active in primary and
inactive in transformed cells.  To test this model the localization of GFP-fused Apoptin
fragments containing either the NLS or NES were analyzed in primary and transformed
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cells.  Figure 2.4 shows that GFP-Ap(42-88), which lacks both the NLS and NES,
displayed a diffuse homogeneous localization pattern in both H1299 and PFF cells,
similar to that of GFP alone.  As expected, the GFP-Ap(1-48) and GFP-Ap(1-88)
mutants, which contain the N-terminal NES but lack the C-terminal NLS, displayed a
predominantly cytoplasmic localization pattern in PFFs.  However, both mutants also
localized to the cytoplasm in H1299 cells, indicating the NES is active in transformed
cells.  Conversely, the GFP-Ap(42-121) and GFP-Ap(82-121) mutants, which contain the
C-terminal NLS but lack the N-terminal NES, localized to the nucleus in H1299 cells as
well as in PFFs, indicating the NLS is active in primary cells.  Thus, the NLS and NES
are active in both primary and transformed cells.  These results suggest that when
uncoupled the NES and NLS function constitutively.
N-terminal NES confers LMB sensitivity.  Next, experiments were performed to
determine whether the elucidated export sequence at the N-terminus of Apoptin was
responsible for the Leptomycin B sensitivity observed in Figure 2.1.  To test this
possibility, the Ap(1-48) and Ap(1-88) derivatives, which are constitutively cytoplasmic
and lack any C-terminal localization sequences, were treated with LMB.  Figure 2.5a
shows that upon LMB treatment, GFP signal is dramatically increased in the nucleus
compared to untreated control cells (quantifications are shown in Figure 2.5b).  These
results indicate that the export sequence contained within this region is a functional
Crm1-dependent NES and can confer the export capability observed with Apoptin.  To
confirm that the NES sequence contained within this domain was required for shuttling
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activity, the Ap-pmNES GFP mutant was tested for shuttling activity using the dnRan
experiment (as in Figure 2.1d).  Figure 2.5c shows that the GFP signal remains in the
nucleus following introduction of dsRed-dnRan indicating that this mutant is defective
for shuttling activity.  Together, these results indicate that the function of the N-terminal
NES sequence is required for Apoptin shuttling activity by virtue of the Crm-1 nuclear
export receptor.
Trans restoration of Apoptin cell type-specific localization through protein
multimerization.  Previous studies have shown that recombinant Apoptin aggregates in
vitro (102), raising the possibility that Apoptin functions as a multimer in vivo.  As a first
test of this possibility it was determined if cell type-specific localization could be restored
in trans by co-expression of two Apoptin fragments, one containing the NLS and the
other containing the NES.  Figure 2.6a shows, as expected, that GFP-Ap-pmNLS, which
lacks a functional NLS, localized to the cytoplasm of both H1299 cells and PFFs,
whereas dsRed-Ap-pmNES, which lacks a functional NES, localized to the nucleus in
both H1299 cells and PFFs.  However, co-expression of GFP-Ap-pmNLS and dsRed-Ap-
pmNES resulted in the localization of both proteins to the nucleus of H1299 cells and the
cytoplasm of PFFs.  These results suggest that Apoptin is a multimer in vivo and confirm
that both localization signals are required for proper cell type-specific localization.
To confirm that Apoptin is a multimer in vivo and to map the multimerization
domain a series of co-immunoprecipitation experiments were performed.  H1299 cells
were transfected with a series of GFP-fused Apoptin derivatives and 12 hours later
60
infected with Flag-tagged Ad-Apwt.  Twenty-four hours after infection, Flag-Apoptin
was immunoprecipitated and the immunoprecipitate analyzed by immunoblotting with an
anti-GFP antibody.  Figure 2.6b shows that only derivatives containing the N-terminal
third of Apoptin [GFP-Apwt, GFP-Ap(1-48), GFP-Ap(1-88)] co-immunoprecipitated
with the Flag-Apoptin, indicating that this region mediates protein multimerization.
To confirm the results of the co-immunoprecipitation experiments and to verify
that multimerization is the basis for restoration of cell type-specific localization in trans,
three additional Apoptin derivatives were analyzed in the trans-expression assay.  Figure
2.6c shows that expression of dsRed-Apwt restored nuclear localization to the
constitutively cytoplasmic GFP-Ap(1-88) mutant in transformed cells and maintained
cytoplasmic localization in primary cells.  By contrast, dsRed-Ap(82-121) failed to alter
cytoplasmic localization of GFP-Ap(1-88) in transformed cells, indicating that the N-
terminal multimerization domain is required for trans-association of the localization
signals.  These results show that the activity of a constitutively cytoplasmic mutant can
be restored by expressing an NLS-containing C-terminal fragment in trans.
The specific Apoptin NES is required for cell type-specific localization.  To determine
if the specific Apoptin NES and NLS sequences were required for cell type-specific
localization, heterologous localization signals were functionally substituted for Apoptin
sequences.  Figure 2.7a shows that replacement of the Apoptin NLS with that of SV40
large T antigen (Ap-SV40NLS) resulted in nuclear localization in H1299 cells and
predominantly cytoplasmic localization in PFFs.  Thus, the SV40 large T antigen NLS
61
can functionally substitute for the Apoptin NLS and the specific Apoptin sub-sequence is
not critical for regulated localization behavior.  By contrast, replacement of the Apoptin
NES with that of Rev (Ap-RevNES), a well established, prototypical NES (75, 115, 187),
resulted in a similar localization pattern in both H1299 and PFFs, indicating that the
specific sequence of the Apoptin NES is critical for proper cell type-specific localization.
Apoptin NES and multimerization domains overlap.  One explanation for the failure
of the Rev NES to functionally substitute for the Apoptin NES is that the Apoptin NES
provides an activity in addition to nuclear export.  Because both the NES and
multimerization domain map to the N-terminus, it was reasoned that the NES might be an
essential part of the multimerization domain.  To test this possibility, the two NES
derivatives, Ap-pmNES and Ap-RevNES, were analyzed for their ability to multimerize
in the co-immunoprecipitation assay.  Figure 2.7b shows that compared to GFP-Apwt,
the GFP-Ap-pmNES mutant showed a comparable (albeit slightly reduced) ability to
interact with Flag-Apoptin.  Significantly, GFP-Ap-RevNES, which contains a functional
NES that differs at multiple residues from the Apoptin NES, failed to detectably co-
immunoprecipitate with Flag-Apoptin.  Interestingly, the intermediate level of
multimerization observed with the Ap-pmNES mutant was sufficient to confer function
in the trans assay; however, close inspection of Figure 2.6 (and data not shown) revealed
that Ap-pmNES was less effective than wild type Apoptin in mediating trans
localization, which presumably reflected the decreased multimerization efficiency.
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Together, these results suggest that the Apoptin multimerization domain overlaps with
the NES.
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Discussion
In this report, it was shown that Apoptin is a nucleo-cytoplasmic shuttling protein
whose localization is mediated by an N-terminal CRM1-dependent nuclear export signal
(NES) and a C-terminal bi-partite nuclear localization signal (NLS).   Interestingly, these
domains impart Apoptin with particular sub-cellular trafficking behavior, as well as the
biochemical properties and protein interactions that provide the basis for cell type-
specific localization.  Based upon the results presented here, a working model for how
Apoptin localization is regulated between primary and transformed cells is discussed.
In primary cells, Apoptin forms large insoluble aggregates mediated by N-
terminal multimerization activity providing a basis for cytoplasmic retention.  It was
found that although Apoptin shuttles in such cell types, this shuttling is restricted to a
small soluble pool of Apoptin proteins most likely in equilibrium with the vast insoluble
and sequestered population (Figure 2.1b).   Activities present in transformed cells induce
steady state levels of Apoptin to increase in the nucleus where a smaller, more soluble
multimeric form can exist.  In this case the majority of Apoptin is mobile and engaged in
nucleo-cytoplasmic shuttling as well as events that will lead to the induction of apoptosis
(Figure 2.1d).
Based on the experiments of Figures 2.4 and 2.6, it is apparent that Apoptin cell
type-specific localization behavior is dependent on the presence of both localization
domains.  When uncoupled, each localization sequence is constitutively active suggesting
that interplay between the two establishes different localization patterns depending on
cell type-specific conditions.  Moreover, the shuttling experiments of Figure 2.1 suggest
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that changes in Apoptin biochemistry in transformed cells shift the equilibrium of
shuttling toward higher steady-state levels in the nucleus.  It is likely that changes in
Apoptin conformation dictate which localization signal has greater effect: the NES region
being dominant in primary cell types and the NLS region being dominant in transformed
cells.  This would explain the necessity for both localization domains to establish cell
type-specific localization, as alternate regions of the protein would be needed for
inhibition of the opposing sequence.  Consistent with this model, recent studies have
demonstrated that Apoptin localization sequence masking may occur at the C-terminus
and that an NLS dominant form exists in transformed cells, whereas this sequence is less
accessible in primary cell types (177).
Since CAV is often found to associate with other viruses that encode dominant
oncogenes, including Marek’s Disease Virus and Avian Adenovirus (116, 167, 192), it is
understandable that Apoptin has evolved a mechanism that senses transformation. The
equilibrium dynamics of Apoptin nucleo-cytoplasmic shuttling provides a powerful
mechanism to induce rapid changes in protein localization with minimal changes in
cellular activities.  Such rapid changes in protein localization and induction of apoptosis
may be important for the timing of CAV life cycle and viral egress.  Overlapping
functional domains is a common theme among many viruses with compact genomes. The
evolution of NES and NLS sequences that overlap with protein interaction domains is
therefore not surprising and provides a means by which localization can be elegantly
regulated by direct interaction.  The existence of such a mechanism has been implicated
in the regulation of at least one other viral protein, HIV-1 Rev.   Like Apoptin, Rev
65
contains both an NES and NLS and shuttles between the nucleus and cytoplasm (114).
The Rev NES is bound by the nuclear kinesin-like protein REBP (Rex/Rev effector
binding protein) that, in turn, stimulates nuclear export by the CRM1 receptor (172).  The
Rev NLS overlaps with an RNA binding domain that contacts the RRE (Rev responsive
element) RNA stem loop structure within the HIV-1 genome resulting in localization
change (35).  Interestingly, Rev NLS activity is sensitive to the multimerization state of
the protein (36).
The multimerization state of Apoptin appears to vary in degree between cell types
and may affect Apoptin’s localization and apoptotic activities.  A higher state of
multimerization in primary cells could explain the aggregation, insolubility and retention
of Apoptin in the cytoplasm.  It has proven difficult to isolate mutations that target
multimerization without affecting export suggesting that these two activities may be very
tightly coupled.  For this reason it is unclear whether multimerization activity is required
for Apoptin localization and activities.
The nature of the cell type-specific modification remains unclear.  However, one
suggestion has been that Apoptin is regulated through phosphorylation by a transformed
cell-specific kinase.  Previous studies have reported that Apoptin is differentially
phosphorylated in transformed and primary cells on threonine-108 (151), which is located
between the two halves of the bipartite NLS (see Appendix).  Additionally, it has been
suggested that an alternate, non-canonical export sequence may exist in this area and that
phosphorylation at T108 could modulate Apoptin localization (140). By contrast, Figure
2.7 indicates that the C-terminal region containing the T108 phosphorylation site and
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proposed alternate export region are dispensable for regulated localization: Apoptin
derivatives in which this domain is substituted by heterologous sequences that lack this
phosphorylation and putative export site localize normally.  These data are consistent
with other studies that show the Apoptin NLS region does not confer the transformed
cell-specific localization observed with the wild type protein (176).  Contrary to Wadia et
al. however, no evidence was found that the cellular concentration of Apoptin has any
effect on localization as overexpression studies by plasmid vector or adenovirus retain
normal cell type specific localization.  Instead, the results in this report clearly
demonstrate that Apoptin’s regulated localization is solely dependent on the presence the
N-terminal multimerization and export domain, which is LMB sensitive, and functional
to confer the export properties observed for Apoptin.  Derivatives lacking this region
have neither the ability to undergo cell type-specific localization nor shuttling activity
(Figures 2.5 and 2.7). This is in contrast to previous studies that report the N-terminal
NES to be non-functional or to enhance nuclear entry (140).
Transformed cell-specific activities other than that of a kinase can be envisioned
and have yet to be explored.  For example, recent studies have found that the second of
three CAV proteins, VP2, functions as a dual specificity protein phosphatase, the
function of which is essential for CAV proliferation (135, 136).  Cell type-specific
regulation of exogenously expressed Apoptin may involve de-phosphorylation of key
residues by a surrogate cellular phosphatase.   Several putative Apoptin phosphorylation
sites are adjacent to proline residues and are thus potential targets for peptidyl-prolyl
isomerase activity as well.  A transformed cell-specific isomerization event could result
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in a conformational change, which may establish a form of Apoptin competent for
induction of apoptosis.  Alternatively, Apoptin may be acted upon by a chaperone, which
could also result in a conformational change as well.  Notably, increased chaperone
activity has been reported in cancer cells (58).  Consistent with this idea, Apoptin has
been reported to be activated by the N-terminal J domain of SV40 large T antigen (193),
which binds to and stimulates activity of Hsp-70 family members (46).  Identification of
the critical Apoptin modifying activity is expected to provide new insights into common
properties of transformed cells.
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Figure 2.1. Apoptin shuttles between the nucleus and cytoplasm in a Crm1-
dependent manner. (A) Immunofluorescence of PFF and H1299 cells 24 h post-
infection with Ad-Apwt. Cells were stained with an -FLAG antibody or DAPI
(magnification 1000X). (B) PFF cells are infected with Ad-wtAp and 24 hours later are
treated or not treated with leptomycin B (LMB) for 3 hours. Cells were fixed and
Apoptin localization was monitored by immunofluorescence using -Flag antibody. (C)
PFF cells expressing GFP-Apwt were treated in the presence or absence of LMB. 3 h
later, Apoptin localization was visualized by fluorescence microscopy for GFP, and
nuclei were visualized by DAPI staining. (D) H1299 cells were transfected with a
construct expressing dsRed-dnRan either alone (top panel) or 12 h following transfection
with GFP-Apwt (bottom panel). As a control, H1299 cells were also transfected with
either a GFP Rev-GFP fusion alone, Rev-GFP plus dsRed-dnRan, or GFP-Apwt (middle
panels). 12 h following transfection, localization was monitored by fluorescence
microscopy for dsRed or GFP and by DAPI staining.
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Figure 2.2. Apoptin nuclear localization is mediated by a dominant transformed
cell-specific activity. (A) Heterokaryon assay.  PFFs expressing GFP-Apwt and H1299
cells expressing dsRed-Apwt were either mixed or plated separately, incubated for 12 h,
and subjected to polyethylene glycol-induced fusion.  (B) Immunofluorescence of HA-1
cells infected with an adenovirus expressing Flag-tagged Apoptin (Ad-Apwt) pre-crisis
(passage 44; upper panels) and post crisis (passage 94; lower panels).  Cells were stained
with an -Flag antibody or DAPI.  (C) The solubility of Apoptin in PFF and H1299 cell
extracts was monitored by immunoprecipitation using an -Flag affinity resin, and the
presence of Apoptin in the immunoprecipitate (IP) (top) and whole cell extract (WCE)
(bottom) was monitored by immunoblot analysis. (D) The solubility of Apoptin was
monitored as above in PFF cells following either treatment or no treatment with LMB for
3 hours.
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Figure 2.3.  Apoptin contains functional NES and NLS sequences.  (Top) Schematic
diagrams of N-terminal GFP-tagged Apoptin NES and NLS mutants.  (Bottom) H1299
and PFF cells expressing GFP-Apoptin mutants were monitored by fluorescence
microscopy for GFP and DAPI staining.
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Figure 2.4.  Apoptin fragments containing either the NES or NLS fail to undergo
cell type-specific localization.  (Top) Schematic diagrams of GFP-Apoptin deletion
mutant derivatives.  (Bottom) Fluorescence microscopy of GFP and DAPI signals in
H1299 and PFFs expressing GFP-Apoptin derivatives.
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Figure 2.5 Apoptin NES sequence within the N-terminus confers LMB sensitivity
and is required for nucleo-cytoplasmic shuttling activity.  (A) H1299 cells expressing
GFP-Ap(1-48) or GFP-Ap(1-88) were treated with LMB or left untreated.  3 h later,
Apoptin localization was visualized by fluorescence microscopy for GFP, and nuclei
were visualized by DAPI staining. (B) Quantitation of the nuclear/cytoplasmic GFP
signal ratio in the presence and absence of LMB. (C) DnRan shuttling assay, performed
as described in Fig. 2.1D using GFP-Ap-pmNES mutant.
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Figure 2.6.  Apoptin localization signals are modular and can cooperate in trans to
confer cell type-specific localization.  (A) H1299 and PFF cells expressing GFP-Ap-
pmNLS, dsRed-Ap-pmNES or both were monitored by fluorescence microscopy.  (B)
H1299 cells were transfected with GFP-Apoptin mutants and 12 h later infected with Ad-
Apwt.  Apoptin multimerization was monitored by immunoprecipitation of Flag-tagged
Apoptin using -Flag affinity resin followed by analysis of the immunoprecipitate (IP)
for GFP-Apoptin by immunoblotting with an -GFP antibody.  Expression of the GFP-
Apoptin mutants was also monitored in WCE.  (C) H1299 and PFF cells were co-
transfected with GFP-Ap(1-88) and either dsRed-Apwt, dsRed-Ap-pmNES or dsRed-
Ap(82-121) and monitored by fluorescence microscopy.
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Figure 2.7. An overlapping Apoptin NES/multimerization domain is required for
cell type-specific localization. (A) Fluorescence microscopy of H1299 and PFFs
expressing GFP-Apoptin derivatives in which either the NLS was replaced by the SV40
NLS (top) or the NES was replaced by the HIV-1 Rev NES (bottom). (B) Apoptin
multimerization was monitored as described in Figure 2.6b.
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CHAPTER III
CAV APOPTIN ASSOCIATES WITH THE ANAPHASE-PROMOTING
COMPLEX/CYCLOSOME TO INDUCE G2/M CELL CYCLE ARREST AND
APOPTOSIS IN THE ABSENCE OF P53
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Abstract
The majority of human cancers lack the tumor suppressor p53, rendering them
refractory to conventional chemotherapeutic agents.  It is therefore critical to identify
p53-independent apoptotic pathways. The Chicken Anemia Virus Apoptin protein
induces apoptosis in transformed cells in the absence of p53 by a mechanism that remains
to be elucidated.  Here using affinity-purification and mass spectroscopy it was found that
in vivo, Apoptin is associated with APC1, a subunit of the anaphase-promoting
complex/cyclosome (APC/C). The APC/C is required to establish a mitotic cell-cycle
checkpoint, and its inhibition results in G2/M arrest and apoptosis. Expression of wild
type Apoptin in transformed cells inhibits APC/C function and induces G2/M arrest and
apoptosis, whereas Apoptin mutants that are unable to associate with APC1 have no
effect.  In p53 null cells, ablation of APC1 by RNA interference induces a G2/M arrest
and apoptosis analogous to that observed following Apoptin expression.  Furthermore,
Apoptin was found to induce the formation of PML bodies and to recruit APC/C subunits
to these nuclear structures. Thus, these results explain the ability of Apoptin to induce
apoptosis in the absence of p53 and suggest a mechanism involving sequestration and
inhibition of the APC/C.  This study is consistent with previous reports that mechanisms
of apoptosis involving G2/M arrest and APC/C modulation lead to p53-independent
apoptosis, and suggests that the APC/C may be an attractive target for the development of
anti-cancer drugs.
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Introduction
Apoptosis is a physiological form of cell death that is required during normal
development and plays a key role in controlling disease by mediating the elimination of
cancerous or virus-infected cells.  Many animal viruses have been found to regulate
apoptosis (reviewed in (152, 166)).  Inhibition of apoptosis can maximize viral
replication efficiency and help evade an immune response.  Conversely, induction of
apoptosis near the end of virus replication facilitates viral egress.
Development of novel and effective cancer therapies depends upon the discovery
of agents that selectively destroy tumor cells while leaving normal cells intact. Several
viruses have been demonstrated to have such selective intrinsic oncolytic activity or have
been engineered to become oncolytic (reviewed in (90, 91)). The Chicken Anemia Virus
(CAV) Apoptin protein is a 13.6 kDa protein that can induce apoptosis in a variety of
human malignant cell lines (196).  Two properties of Apoptin-induced cell death are
particularly intriguing:  first, Apoptin does not induce apoptosis in normal
(untransformed) cells; and second, Apoptin-induced cell death is not dependent upon the
p53 tumor suppressor (37, 38).  Thus, Apoptin represents a potential agent for the
treatment of tumors that have lost their p53 status and are therefore refractory to many
cancer therapies. Apoptin has shown efficacy in treating human xenografted tumors in
mice and is currently being evaluated as a gene therapy agent to selectively destroy
cancer cells (169).
The molecular mechanism by which Apoptin induces apoptosis is largely
unknown.  Several studies have demonstrated that nuclear localization of Apoptin is
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required for induction of apoptosis (42, 67), suggesting the cellular target of Apoptin is a
nuclear protein.  In this study, in vivo Apoptin is shown to be associated with subunit 1 of
the anaphase-promoting complex/cyclosome (APC/C).
This study examines the consequences of an Apoptin interaction with the APC/C.
Functional analysis reveals that Apoptin expression results in inhibition of APC/C
activity specifically in transformed cells.  This inhibitory action results in G2/M cell
cycle arrest and induction of p53-independent apoptosis.  These data reveal a mechanism
for Apoptin p53-independent apoptosis and suggest inhibition of the APC/C as a novel
potential target area for the development of anti-cancer drugs.
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Materials and methods
Cells and adenoviruses.  Saos-2, H1299, and primary foreskin fibroblast cells (PFFs)
were obtained from ATCC and maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum plus 10 mg/ml streptomycin and 10 U/ml
penicillin (Sigma) at 37°C under 5% CO2 (95% air).
Apoptin adenovirus (Ad-Apwt), Ad-Ap-pmNES, and LacZ adenovirus (Ad-LacZ)
were prepared as previously described (Chapter II).  All cells were infected at
approximately 80% confluence at an MOI of 35. Adenovirus was added to cells in a
minimal volume of culture media and gently agitated at 37°C under 5% CO2 for 1 h.
Following infection, culture media was added and cells were incubated for indicated
times.
Plasmid constructions. Flag-Apoptin deletion constructs were sub-cloned from the
GFP-Apoptin deletion panel (previously described in Chapter II) via EcoRI and BamHI
and directionally cloned into the p3XFLAG-myc-CMV-26 vector (Sigma) to construct an
in-frame N-terminal fusion to the FLAG epitope. Stop sequences were generated to
exclude the C-terminal myc tag.  Ap-pmNLS was constructed as previously described
(Chapter II).  Ap-pmNLS2 constructs were generated by site-directed mutagenesis of
indicated sequences followed by directional cloning via EcoRI and BamHI into both the
pEGFP-C1 (Sigma) or p3XFLAG-myc-CMV-26 vectors for N-terminal fusions.  CFP-
PML was a kind gift from Dr. Claude Gazin (UMass Medical School). Constructs were
verified by restriction digest analysis and DNA sequencing.
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Immunofluorescence. H1299 cells were transiently transfected using Effectene reagent
(Qiagen) and after 16 hr, fixed in 4% paraformaldehyde and stained with either -Cdc27 mAb
(Santa Cruz) or -PML mAb (Santa Cruz) followed by Cy3 conjugated -mouse 2 Ab.  Cells
were mounted on slides and observed using a Ziess Axiophot2 fluorescence microscope using
Axiovision 4.2 software.
Immunoprecipitations . For affinity purification, ~8 x 107 cells were infected with FLAG-
tagged Ad-Apwt.  After 24 h, cells were washed in PBS, harvested by scraping, and lysed in
Buffer X [50 mM Tris, pH 8.5, 250 mM NaCl, 1 mM EDTA, 1% NP40, Complete Mini tablet
(Roche)] on ice for 20 min.  Following centrifugation, lysates were pre-cleared with Protein
A/G-agarose for 1 h followed by incubation with FLAG-agarose at 4°C for 4 h.  Beads were
washed in Buffer X and eluted using FLAG-peptide.  Eluates were resuspended in 1X SDS
sample buffer and boiled for 5 min.  Proteins were resolved by SDS-PAGE and visualized by
silver staining using the SilverQuest kit (Invitrogen).  Bands were excised and submitted for
MALDI-TOF mass spectrometry to the Proteomic Mass Spectrometry Lab at UMass Medical
School.
For co-immunoprecipitations, ~2 x 107 cells were infected with Ad-Apwt or Ad-
LacZ and harvested and lysed as described above.  Following centrifugation, supernatants
were incubated with 20 μl equilibrated EZview Red -Flag M2 affinity beads (Sigma) at
4°C for 4 h.  Beads were washed in Buffer X and bound proteins were eluted in 1X SDS
sample buffer by boiling for 5 min.
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For APC1 association domain mapping, ~1 x 107 cells were transiently transfected
with 3XFLAG-Apoptin truncation mutants using Effectene reagent.  After 48 h, cells
were processed as described for the co-immunoprecipitation experiments.
Gel filtration chromatography. H1299 cells (~2 x 107) were either mock- or Ad-Apwt-
Infected, and after 24 h cells were washed in PBS, harvested by scraping, and lysed in
Buffer A [20 mM Tris, pH 7.5, 100 mM NaCl, 20 mM -glycerophosphate, 0.2% NP-40,
10% glycerol, 0.5 mM DTT, Complete Mini Tablet (Roche)] on ice for 30 min.  Lysates
were sonicated for ~10 sec, centrifuged for 1 h at 100,000g, and ~500 mg of total protein
was injected into a Pharmacia FPLC apparatus and separated on a Superose 6 10/30
(Pharmacia) column.  Fractions (500 μl) were collected and precipitated with 20%
trichloroacetic acid (TCA) on ice for 1 h.  Precipitates were then centrifuged at 13,000g
for 15 min, washed with –20°C acetone, dried, resuspended in 1X SDS sample buffer and
boiled for 5 min.
Immunoblotting.  Proteins were resolved by SDS-PAGE and transferred to
nitrocellulose.  Blots were blocked with 5% milk in TBS-T and probed with either -
FLAG M2 monoclonal (Sigma), -APC1 polyclonal (affinity purified a-peptide serum),
-Cdc27 monoclonal (Santa Cruz); -cyclin B1 (Upstate Biotech); -Plk (Zymed
Laboratories, Inc.), -cyclin E (Upstate Biotech); or -tubulin (Sigma) antibodies
followed by appropriate HRP-conjugated -Ig secondary antibody (Amersham
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Biosciences). Protein bands were visualized by chemiluminescence using SuperSignal
Substrate (Pierce).
Apoptosis and cell cycle assays. To generate kill curves, Ad-Apwt- Ad-Ap-pmNES and
Ad-LacZ-infected H1299, Saos-2 and PFF cells were harvested by trypsinization, washed
in PBS, and monitored for cell viability by trypan blue exclusion. For additional cell
viability assays, H1299 and PFF cells infected with Ad-Apwt, Ad-pmNES or Ad-LacZ
were harvested, washed in PBS, and stained with ViaCount reagent (Guava
Technologies), and viability was quantified using a Guava Personal flow cytometer.  Data
points were collected as percent cell viability per 5000 events.  Apoptotic assays using
GFP-Apoptin deletion mutants were performed by transfecting the deletion panel into
H1299 cells, and 4 d later, cells were fixed with 4% paraformaldehyde and stained with
DAPI.  Percent apoptosis was scored as the percent of 100 GFP positive cells showing
apoptotic morphology.  Results were collected in a blind study by at least three
individuals in two separate experiments.  Data was graphed after subtraction of GFP
background; all mutant samples are shown as percent apoptosis of wild type.  For
Annexin V analysis, cells were stained using the Annexin V-PE Apoptosis Detection Kit-
I (BD Pharmingen) and analyzed using a Guava Personal flow cytometer (Guava
Technologies, Inc.).   Data points were collected as percent Annexin V positive cells per
5000 events.
For cell cycle analysis, cells were harvested by trypsinization, fixed and stained
with propidium iodide, and analyzed by FACS.  To establish cell synchrony, H1299 cells
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were treated with 100nM nocodazole for 12 hours followed by mitotic shake-off.
Detached cells were collected, washed and re-plated without nocodazole.  Procedure was
repeated 3 times.
RNA interference. Double-stranded RNAs (ds-RNAs) were synthesized in vitro using a
500 bp PCR fragment as the template.  Primer sequences, containing T7 priming sites,
were as follows: APC1,
5'GCGTAATACGACTCACTATAGGGAGAAAAGGAGTAAGTGAAATTGG-3' and
5'-GCGTAATACGACTCACTATAGGGAGAGGAAAGGTGAAGTCACAGGG-3';
Lamin A/C,
5'GCGTAATACGACTCACTATAGGGAGAGGCAGTCTGCTGAGAGGAAC-3' and
5'-GCGTAATACGACTCACTATAGGGAGAAGGTGTTCTGTGCCTTCCAC-3'. In
vitro transcription was performed using the T7 Megascript Kit (Ambion), and the ds-
RNA products were cleaved using the Dicer siRNA Generation Kit (Gene Therapy
Systems, Inc.).  The pool of diced-siRNAs was then transfected into cells using
Oligofectamine (Invitrogen) as described previously (55).
91
Results
Apoptin induces apoptosis specifically in transformed cells in the absence of p53. To
demonstrate Apoptin p53-independent and cell type-specific killing ability, both normal
and p53-null transformed cells were infected with Ad-Apwt (Chapter II) and monitored
over 4 days.  Figure 3.1a shows that following infection with Ad-Apwt, p53 null SAOS2
osteosarcoma cells underwent pronounced apoptosis after 24 hours, and most cells were
dead by 72 hours.  Little or no death was observed in cells infected with a control
adenovirus expressing LacZ (Ad-LacZ).  Similar results were obtained in H1299 cells, a
p53 negative non-small cell lung carcinoma cell line.  By contrast, Apoptin expression in
normal PFF cells had no apoptotic effect, as was the case with Ad-LacZ infected controls.
Apoptin protein expression was confirmed by immunoblot assay using an -FLAG
monoclonal antibody (Figure 3.1b). Transformed cell death was concurrent with Apoptin
expression.
Apoptin co-immunoprecipitates with subunit 1 of the anaphase-promoting complex.
To identify Apoptin-associated cellular proteins, extracts were prepared from Ad-Apwt
infected H1299 cells and Apoptin was purified using -FLAG affinity resin. Apoptin and
associated proteins that bound to the affinity column were separated by SDS-PAGE and
visualized by silver staining.  MALDI-TOF mass spectroscopic analysis revealed that a
major Apoptin-associated polypeptide was APC1, the largest subunit of the APC/C and
an essential component of the mitotic checkpoint apparatus (Figure 3.2a).  Apoptin also
co-immunoprecipitated with HSP-70, which is known to associate with over-expressed
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proteins, as well as -tubulin, -tubulin and -actin, suggesting an association with
filamentous networks, consistent with the immunocytochemistry results previously
described (Figures 2.1a and 2.2b).
To confirm the Apoptin-APC1 association, Apoptin was immunoprecipitated
from Ad-Apwt-infected H1299 cells with the -FLAG antibody and the
immunoprecipitate analyzed for APC1 by immunoblotting.  Figure 3.2b shows that APC1
was present in the Apoptin immunoprecipitate but not in the immunoprecipitate of a
control LacZ protein. By contrast, Figure 3.2c shows that APC1 was not present in the
immunoprecipitate of PFF cells indicating that the Apoptin-APC1 association is specific
to transformed cells.
Apoptin expression in transformed cells induces G2/M cell-cycle arrest by inhibition
of APC/C function. The association of Apoptin with APC1 raised the possibility that
Apoptin expression could affect cell-cycle progression.  To address this issue, H1299 and
PFF cells were infected with Ad-Apwt or Ad-LacZ and analyzed by fluorescence
activated cell sorting (FACS).  Figures 3.3a-b show that following infection with Ad-
Apwt, H1299 cells began to accumulate in G2/M after 12 h, whereas the cell-cycle
profile of PFF cells was unaffected.  Although FACS analysis of Apoptin-expressing
H1299 cells clearly showed a 4N DNA content, morphological examination did not
reveal a classical mitotic-arrested appearance but rather a condensed nuclear morphology
that is a hallmark of apoptosis.  The onset of apoptosis was rapid, as evidenced by the
appearance of a prominent sub-G1 peak concomitant with G2/M accumulation.
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To determine whether cell cycle arrest is a prerequisite for induction of apoptosis,
H1299 cells were synchronized by repeated rounds of mitotic shake-off and were infected
with Ad-Apwt in parallel with asynchronous cells.  After 24 hours, cells were harvested
and analyzed for cell viability.  Figure 3.3c shows that at 24 hours asynchronous H1299
cells underwent a marginal amount of apoptosis similar to that observed in Figure 3.1a.
Synchronous cells, by contrast, showed a significant increase in the percent of apoptotic
cells and underwent cell death simultaneously as a large population.  These data suggest
that Apoptin induced apoptosis is activated in response to the state of the cell cycle and
additionally, that the G2/M arrest observed with Apoptin expression may be a
prerequisite for cell death.
Apoptin expression results in disruption of the APC/C. To verify that Apoptin
inhibited APC/C function, an independent assay was used to measure APC/C activity.
APC/C catalyzes the ubiquitination of several substrates including cyclin-B1 and Polo-
like kinase (Plk), whose degradation by the proteasome results in anaphase progression
and mitotic exit (reviewed in (134)).  If APC/C is inhibited, these substrates are not
degraded and remain in the nucleus.  Thus, stabilization of APC/C substrates is indicative
of cyclosome dysfunction (189).  To test whether Apoptin expression resulted in
stabilization of APC/C substrates, H1299 cells were infected with Ad-Apwt, Ad-LacZ or
mock-infected, and 24 hours later levels of mitotic APC/C substrates were determined by
immunoblotting.  As a positive control, cells were arrested in G2/M by nocodazole
treatment.  Figure 3.4a shows that cyclin-B1 was stabilized in Apoptin-infected and
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nocodozole-treated cells compared to Ad-LacZ-infected cells.  In contrast, protein levels
of cyclin E, a G1 cyclin that is not an APC/C substrate, were slightly decreased by
Apoptin expression or nocodazole treatment.  RT-PCR analysis confirmed that Apoptin
did not affect cyclin B1 or Plk mRNA levels (Figure 3.4b).  These data suggest that
Apoptin inhibits cyclosome function leading to G2/M arrest and apoptosis.
To gain insight into how Apoptin might inhibit APC/C activity, gel filtration
analysis of the APC/C was performed in mock- or Ad-Apwt-infected H1299 cells.
Fractions from the gel filtration column were analyzed by immunoblotting for APC1 or
another APC/C subunit, Cdc27 (APC3).  The results of Figure 3.4c reveal two dramatic
effects of Apoptin expression on the APC/C.  First, following Apoptin expression, both
APC1 and Cdc27 eluted later consistent with lower native molecular weights, strongly
suggesting disruption of the APC/C.  In fact, in Apoptin-expressing cells some APC1
migrated at the size expected for a free subunit (~200 kDa).  Second, in Apoptin-
expressing cells Cdc27 degradation products appeared in the lower molecular weight
range.  Collectively, these results suggest a model in which Apoptin binds to APC1,
leading to disruption of the APC/C and the resultant degradation of some APC/C
subunits.  Finally, it is noteworthy that despite its small size (13.6 kDa), essentially all
Apoptin migrated at a native molecular weight of ~200 kDa to greater than 1 MDa,
consistent with the possibility that Apoptin is associated with one or more large multi-
subunit complexes.
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The Apoptin NLS and nucleo-cytoplasmic shuttling are involved in APC1
interaction and required for induction of apoptosis.  To delineate the region of
Apoptin required for association with APC1, a panel of FLAG-tagged Apoptin deletion
mutants (Figure 3.5a) was transiently expressed in H1299 cells.  Forty-eight hours
following transfection, Apoptin was immunoprecipitated with -FLAG antibody, and the
immunoprecipitate analyzed for APC1 by immunoblotting.   Figure 3.5b shows that
APC1 was present only in immunoprecipitates of Apoptin derivatives that contained the
C-terminal domain (amino acids 82-121).
To investigate whether association with APC1 is required for Apoptin-mediated
cell death, GFP-derivatives of the Apoptin deletion mutants were transiently expressed in
H1299 cells.  Four days following transfection, cells were fixed, stained with DAPI, and
analyzed by fluorescence microscopy for apoptotic morphology. Figure 3.5c shows that
the ability of mutants lacking the C-terminal (APC1-associating) region to induce cell
death was significantly reduced.  Interestingly, Apoptin mutants Ap(82-121) and Ap(42-
121) retained a relative greater portion of wild-type killing activity suggesting that the C-
terminus alone may have some capacity for induction of apoptosis1.  Collectively, the
results of Figures 3.5b-c indicate that the C-terminal domain of Apoptin is necessary (and
possibly sufficient) for induction of apoptosis and that association with APC1 is
responsible for Apoptin-mediated G2/M arrest and cell death.
1 Similar results were obtained using electroporated Flag-Apoptin deletion mutants and cell viability
analysis via flow cytometry (not shown), however, apoptotic capacities for the deletion mutants compared
to wild type Apoptin are less obvious by this method. This difference may be attributed to the use of GFP
fusions as well as chemical transfection methods, which might result in spurious effects.
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The association of APC1 with the C-terminus of Apoptin prompted examination
of whether NLS sequences within this domain were involved in APC1 association.  To
investigate the role of the NLS region, several candidate mutations were constructed (not
all shown) including one in which lysine-116, arginine-117 and arginine-118 were
mutated to alanine (Ap-pmNLS2; Figure 3.6a).  The majority of this mutant protein
retained nuclear localization in H1299 cells (Figure 3.6b).  Additionally, the Ap-
SV40NLS mutant, which localized exclusively to the nucleus in H1299 cells (previously
described in Chapter II, Figure 2.7a), was also analyzed to verify that N-terminal
sequences did not take part in APC1 association when sent to the nucleus (unlike in
Figure 3.5, where they localize to the cytoplasm).  To determine the ability of these two
mutants to induce cell death in transformed cells, GFP-Apwt, GFP-Ap-pmNLS2 and
GFP-Ap-SV40NLS were transiently expressed in H1299 cells.  Three days after
transfection, cells were fixed, stained with DAPI, and analyzed by microscopy for
apoptotic morphology.  As expected, cells expressing GFP-Apwt underwent pronounced
apoptosis whereas the ability of the Ap-pmNLS2 and Ap-SV40NLS mutants to induce
apoptosis was severely reduced (Figure 3.6c, top).
To understand why the Ap-pmNLS2 and Ap-SV40NLS mutants failed to induce
apoptosis in transformed cells even though they localized to the nucleus, their ability to
interact with APC1 was monitored.  A triple Flag-tagged version of each mutant was
transiently transfected into H1299 cells and immunoprecipitated with an -Flag antibody,
and the immunoprecipitate analyzed for APC1 by immunoblotting.  Interestingly, APC1
was present in the immunoprecipitate from wild type Apoptin, but not in that of the Ap-
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pmNLS2 or Ap-SV40NLS mutants (Figure 3.6c, bottom) despite the presence of both
these mutants in the nucleus.  These observations are consistent with the results in Figure
3.5 and suggest that the NLS sequence overlaps with the domain required for association
with APC1.  Furthermore, these results indicate that nuclear localization in the absence of
APC1 association is not sufficient to induce apoptosis.
 To clarify the involvement of the NES and shuttling activity in Apoptin-induced
cell death, the ability of the Ap-pmNES mutant (Chapter II), which contains a wild type
C-terminal domain and localizes to the nucleus in both transformed and primary cells
(Chapter II, Figure 2.3), to interact with APC1 and induce apoptosis was investigated.
Surprisingly, despite its nuclear localization, this mutant exhibited greatly reduced ability
to interact with APC1 (Figure 3.6d, bottom) and failed to induce apoptosis in transformed
and primary cells (Figure 3.6d, top). Thus, the shuttling activity of Apoptin may be
required for interaction with APC1 and induction of apoptosis.
Loss of APC1 induces G2/M arrest and apoptosis in the absence of p53. The results
described above suggest a model whereby Apoptin inhibits APC/C function resulting in
G2/M arrest followed by apoptosis.  A prediction of this model is that inhibition of APC1
through other means should have a similar effect.  To test this prediction, the
consequence of depleting APC1 by RNA interference (RNAi) was analyzed in H1299
cells.  Figure 3.7a demonstrates that transfection of short interfering RNAs (siRNAs)
directed against APC1 resulted in specific and near complete reduction of APC1 protein
levels, whereas a non-specific control siRNA directed against Lamin A/C had no effect.
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Transfection of an APC1 siRNA resulted in a dramatic reduction in cell density
(Figure 3.7b) and viability (Figure 3.7c) compared to the Lamin A/C siRNA-transfected
and mock-transfected controls. Annexin V-FITC staining confirmed, as expected, that
cell death was due to apoptosis (Figure 3.7d). Figure 3.7e shows that transfection of an
APC1 siRNA, but not control siRNAs, resulted in G2/M accumulation and the
appearance of cells in the sub-G1 region.  Quantification of the FACS data indicates that
nearly 50% of APC1 siRNA-transfected cells were present in G2/M compared with
approximately 15% for the Lamin A/C siRNA- or mock-transfected controls (Figure
3.7e, right panel).  Thus, RNAi-mediated depletion of APC1 results in a phenotype
analogous to that observed following Apoptin expression.
Apoptin co-localizes with the APC/C within PML bodies in the nuclei of
transformed cells. Next, to verify Apoptin’s co-localization with APC/C complexes in
transformed cells, immunofluorescence was performed for the APC/C subunit Cdc27
(APC3), a core subunit routinely used as a marker for APC/C localization (81, 145).
H1299 cells were transiently transfected with a plasmid expressing dsRed-Apwt and
following a 12 hr incubation, fixed and stained with an -Cdc27 antibody.  Figure 3.8a
shows that dsRed-Apwt co-localized with Cdc27 in the nucleus of transformed cells. We
failed to detect Cdc27 immunofluorescence in the presence of the Ap-pmNLS2 mutant,
which does not associate with the APC/C and fails to induce apoptosis (Figure 3.6b-c)
and G2/M arrest (data not shown). This result is consistent with previous reports showing
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that various APC/C subunits, including Cdc27, are not detected by immunofluorescence
in interphase or non-mitosis arrested cells (80, 81, 86).
It has recently been reported that Apoptin associates with PML nuclear bodies
(140).  To verify this result, cells were transfected with either dsRed-Apwt or, as a
control, dsRed-Ap-pmNLS2 and stained with an -PML antibody.  Figure 3.8b confirms
that wild-type Apoptin co-localized with PML bodies within the nucleus of transformed
cells.  Significantly, in cells transfected with dsRed-Ap-pmNLS2, PML
immunofluorescence was undetectable, consistent with previous studies showing that in
H1299 cells, PML nuclear body formation occurs only under conditions of apoptotic
stimulus (44).  Thus, Apoptin induces the formation of PML nuclear bodies in
transformed cells.
By inference, the immunofluorescence experiments of Figures 3.8a-b suggest that
in the presence of Apoptin, APC/C co-localizes with PML nuclear bodies.  To provide
more direct evidence for co-localization of Cdc27 and PML in the presence of Apoptin,
plasmids expressing either dsRed-Apwt or dsRed-Ap-NLS2 were co-transfected into
H1299 cells with a plasmid expressing PML fused to the C-terminus of cyan fluorescent
protein (CFP-PML).  Twelve hours following transfection, cells were fixed and stained
with -Cdc27 antibody.  Figure 3.8c shows that, as expected, dsRed-Apwt, Cdc27 and
CFP-PML co-localized in the nucleus of transformed cells.  Thus, in the presence of
Apoptin, the APC/C becomes sequestered in PML bodies.
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Discussion
Most human cancers have mutations in the p53 gene rendering them refractory to
existing therapies (17, 82, 161). Novel approaches for inducing programmed cell death in
cancers that lack functional p53 would represent a significant advance. The results in this
study suggest that CAV Apoptin induces G2/M arrest and apoptosis in p53 null
transformed cells through association with and disruption of the APC/C.
Inhibition of the APC/C may represent a major tumor suppressor mechanism
(reviewed in (73).  For example, the endogenous APC/C inhibitor RASSF1 is mutated in
some human cancers (6).  Moreover, dysfunction of the APC/C and mitotic checkpoint
function has been suggested to contribute to transformation and could lead to properties
in cancer cells such as unscheduled proliferation and aneuploidy.  In addition to Apoptin,
several viral proteins have been found to interact with the APC/C and deregulate its
activity.  The adenovirus E4orf4 protein also arrests cells in G2/M (95) and induces
apoptosis specifically in transformed cells in the absence of p53 (110).  Yeast genetics
experiments suggest that E4orf4-induced cell cycle arrest is mediated by the APC/C,
most likely through its Cdc16 subunit (95).  More recently, the HTLV-1 Tax protein has
been found to deregulate APC/C activity through association with the Cdc20 activator
protein (106).  Thus, inhibition of the cyclosome complex may represent a convergently
evolved viral cytopathic mechanism and suggests an underlying role for the APC/C as a
nodal point in cell cycle control and tumor suppression.  The evolution of these viruses to
target the APC/C may involve cellular arrest in mitosis to facilitate viral replication.  For
example, mitotic cells become rounded and lift from the surrounding substrate, which
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may provide a means whereby infected cells can become mobilized to areas of uninfected
cells and more efficiently disseminate the virus.
APC1 is suggested to be essential in assembly and regulation of the cyclosome
complex (96, 174).  The preparative IP/mass spectroscopic analysis performed in this
study identified APC1 but not other APC/C subunits suggesting that Apoptin may
associate with free APC1 and not the intact APC/C.  These results suggest a model in
which Apoptin induces either a failure to assemble an APC/C or disassembly of an
existing one and a resultant lack of APC/C activity.
Several previous observations are consistent with the notion that apoptotic
signaling from the mitotic checkpoint apparatus functions independently of p53.   For
example, drugs that suppress microtubule dynamics, such as paclitaxel (Taxol), which
promote mitotic arrest and cell death are generally unaffected by p53 status (45). In fact,
cancer cells that are p53 negative are sensitized to paclitaxel-mediated killing (173, 178).
Other drugs that target terminal steps of the pathway, such as degradation of mitotic
cyclins, have also been shown to be p53-independent.  For example, the proteasome
inhibitor PS-341 (Bortezomib), which is being evaluated for clinical use, induces
apoptosis in cells lacking functional p53 (191). The mechanism of Apoptin-induced cell
death proposed here is therefore consistent with previous observations that the mitotic-
checkpoint apparatus can stimulate apoptosis independent of p53 status. Reports have
indicated that the taxane class of chemotherapeutics as well as other G2/M arresting
drugs, including Bortezomib, induce and/or stabilize BIM leading to onset of apoptosis in
a p53-independent manner (164).  The results presented here indicate that Apoptin may
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act on a similar pathway as a mechanism of p53-independent apoptosis in transformed
cells suggesting a role for BIM mediated apoptosis in tumor suppression.
The results of this study demonstrating Apoptin-mediated induction of PML
nuclear body formation are consistent with those of previous studies showing co-
localization of Apoptin with PML nuclear bodies (140).  Moreover, general induction of
PML nuclear bodies in H1299 cells has been previously demonstrated by a number of
groups (including (44)), which have shown that these cells respond dramatically to
various types of apoptotic stimuli by increasing both the size and number of PML bodies.
PML nuclear bodies play an integral role in apoptotic processes resulting from a variety
of stimuli and have been proposed to serve as a “hub” for nuclear apoptotic reinforcement
(16).  Cells derived from PML-/- knockout mice are virtually resistant to apoptosis
stimulated by intrinsic as well as extrinsic stimuli, indicating a strong connection between
PML body formation and induction or execution of programmed cell death (16).
Interestingly, PML nuclear bodies have been implicated in the execution of p53-
independent (as well as p53-dependent) apoptotic programs (181, 182, 195), an important
requisite for Apoptin induced cell death.
PML nuclear bodies are potential hubs for the control and regulation of proteins
by post-translational modification (e.g., sumoylation, acetylation and ubiquitination) and
by degradation (7, 97, 99).  For example, many cellular and viral sumoylated proteins are
targeted to PML nuclear bodies (153).  In many cases, however, the functional
significance between protein modification and PML localization remains unclear.
Interestingly, studies in yeast have shown that the mitotic functions of the APC/C are
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modulated by sumoylation and ubiquitination (49).  Thus, the Apoptin-mediated
recruitment of APC/C components (or complexes) into PML nuclear bodies suggests a
functional connection between Apoptin-APC/C interaction, cyclosome inhibition and
induction of apoptosis.  Abrogation of APC/C activity through targeting to PML nuclear
bodies provides a method by which APC/C could be sequestered and inhibited, and
apoptotic programming of nuclear origin could ensue.
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Figure 3.1. Apoptin induces apoptosis specifically in transformed cells. (A) Saos-2
and H1299 cells were infected with adenovirus expressing FLAG-Apoptin (Ad-Apwt) or
LacZ (Ad-LacZ), and cell death was monitored for 96 h post-infection by trypan blue
exclusion. (B) Immunoblot analysis using -FLAG antibody to monitor Apoptin protein
expression in Saos-2 cells.
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Figure 3.2. Apoptin is associated in vivo with APC1 in transformed cells. (A) Affinity
purification of Apoptin-associated proteins from H1299 cells infected with Ad-Apwt.
Proteins were separated by SDS-PAGE and visualized by silver staining. Micro-
sequenced bands are indicated. (B) Apoptin was immunoprecipitated from Ad-Apwt-and
Ad-LacZ-infected H1299 cells using -FLAG antibody, and the immunoprecipitates
were analyzed for APC1 by immunoblotting with a polyclonal -APC1 antibody. (C)
Apoptin was immunoprecipitated from Ad-Apwt-infected PFF or H1299 cells using -
FLAG antibody, and the immunoprecipitates were analyzed for APC1 by
immunoblotting. Immunoblotting for FLAG-Apoptin was performed on whole cell
extracts.
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Figure 3.3. Apoptin expression induces G2/M cell cycle arrest specifically in
transformed cells. (A) Cell cycle analysis of H1299 cells infected with either Ad-LacZ
or Ad-Apwt at 0, 12, 24 and 36 h post-infection. (B) Percent of H1299 or PFF cells in
G2/M were quantified. (C) H1299 cells were synchronized and compared to an
asynchronous population 24 hours following Ad-Apwt infection. Levels of apoptosis
were measured using ViaCount reagent on a Guava personal flow cytometer.
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Figure 3.4. Apoptin induces APC/C dysfunction via complex dissociation. (A)
Immunoblot analysis of APC/C substrates cyclin B1 and Polo-like kinase (Plk), and a
non-APC/C substrate, cyclin E, in H1299 whole-cell lysates 24 h following infection with
Ad-Apwt or Ad-LacZ, or in cells treated with nocodozole (noc) for 12 h. Tubulin levels
were monitored as a loading control. (B) RT-PCR analysis of cyclin B1 or Plk mRNA
levels in H1299 cells 24 h following infection with Ad-Apwt or Ad-LacZ, or in cells
treated with nocodozole (noc) for 12 h. GAPDH was monitored as a loading control. (C)
Gel filtration analysis of the APC/C complex in mock- or Ad-Apwt-infected H1299 cells.
Fractions from the gel filtration column were analyzed by immunoblotting for FLAG-
Apoptin, APC1 or another APC/C subunit, Cdc27. Positions of molecular weight
markers are indicated.
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Figure 3.5. The C-terminal domain of Apoptin is required for association with
APC1 and apoptosis. (A) Schematic representations of N-terminal FLAG- or GFP-
tagged Apoptin deletion mutants. (B) H1299 cells were transfected with FLAG-Apoptin
deletion constructs, and 48 h later Apoptin was immunoprecipitated with -FLAG
antibody and the immunoprecipitate analyzed for APC1 and Apoptin by immunoblotting.
(C) H1299 cells were transfected with GFP-Apoptin deletion constructs and 4 d later
fixed and stained with DAPI and analyzed by fluorescence microscopy for GFP
expression associated with apoptotic morphology. The percent apoptosis in cells
expressing GFP alone was taken as background and subtracted from all samples. All
mutant samples are shown as percent apoptosis of Apwt.
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Figure 3.6.  The Apoptin NLS and nucleo-cytoplasmic shuttling are involved in
APC1 interaction and required for induction of apoptosis.  (A) Schematic diagrams of
Apoptin NLS mutations.  (B) Fluorescence microscopy of H1299 cells expressing GFP-
Ap-pmNLS2.  (C) (Top) Apoptosis assays.  H1299 cells were transfected with GFP-
Apwt, GFP-Ap-pmNLS2 or GFP-Ap-SV40NLS and after 72 h, fixed, stained with DAPI
and analyzed by fluorescence microscopy for GFP expression associated with apoptotic
morphology.  The percent apoptosis in cells expressing GFP alone was taken as
background and subtracted from all samples.  All mutant samples are shown as percent
apoptosis of GFP-Apwt.  (Bottom) APC1 association.  H1299 cells expressing Flag-
tagged versions of Apoptin mutants were immunoprecipitated with an -Flag antibody
and the immunoprecipitate analyzed for APC1 and Apoptin by immunoblotting.  (D)
(Top) PFF or H1299 cells were infected with Ad-LacZ, Ad-Apwt or Ad-Ap-pmNES, and
72 h later cell viability was quantified by flow cytometry.  (Bottom) APC1 association.
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Figure 3.7. Depletion of APC1 by RNA interference induces G2/M arrest and
apoptosis in the absence of p53. (A) Immunoblot analysis of H1299 cells transfected
with 0, 0.05 and 0.5 μg siRNAs directed against either Lamin A/C or APC1. Tubulin
was monitored as a loading control. (B) Crystal violet staining of H1299 cells following
two rounds of transfection with Lamin A/C or APC1 siRNAs, or mock-transfected. (C)
Cell viability assays of H1299 cells 48 h following transfection of siRNAs, or mock-
transfected. (D) Annexin V-FITC staining to monitor apoptosis in siRNA-transfected
cells. (E) Cell cycle analysis (left) and quantification of the percentage of cells arrested in
G2/M (right) of siRNA-transfected cells.
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Figure 3.8.  Apoptin co-localizes with APC/C within PML bodies in the nuclei of
transformed cells.  (A, B) H1299 cells were transiently transfected with a plasmid
expressing either dsRed-Apwt or dsRed-Ap-pmNLS2 and following a 12 hr incubation,
fixed and stained with -Cdc27 antibody (A) or an -PML antibody (B).  (C) H1299 cells
were co-transfected with plasmids expressing either dsRed-Apwt or dsRed-Ap-NLS2 and
a plasmid expressing CFP-PML. 12 hr following transfection, cells were fixed and
stained with -Cdc27 antibody.
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CHAPTER IV
CONCLUSIONS AND PERSPECTIVES
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Conclusions
The results of this study have yielded insight into the mechanism of tumor cell-
selectivity of the CAV Apoptin protein as well as provided a novel p53-independent
pathway to apoptosis in transformed cells.  Since CAV is often found to co-infect cells
with several other transforming viruses, it is understandable to find that this virus carries
a protein activity that senses and responds to the transformation state of the cell.
Several Apoptin characteristics are influenced by early events in cellular
transformation including the degree of self-association of the protein, intracellular
solubility, and sub-cellular trafficking (Chapter II).  In primary cell types, Apoptin is
functionally inert owing to the large degree of cytoplasmic aggregation, low steady-state
level of shuttling protein, and inaccessibility of the nucleus.  Transformation dramatically
increases the soluble shuttling pool of Apoptin protein, and resultant steady-state levels
of protein increase in the nuclear compartment.  Presumably a modification that affects
aggregation and N-terminal function could lead to these overall changes in protein
behavior.  Those modifications previously discussed, including modulation of
phosphorylation and/or conformational changes, are formally possible.  Conformational
changes that would dampen the activity of the N-terminal export/multimerization domain
and expose the NLS region in the C-terminus could lead to such an equilibrium shift (see
Figure 4.1b).  Consistent with these ideas, recent studies have suggested that Apoptin
conformational changes may occur in transformed cells to unmask an otherwise
inaccessible NLS at the C-terminus (177).  Studies involving masking of the NES and
Crm1 binding have yet to be performed, but may reveal a similar strategy for regulation
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at the N-terminus.  Notably, regulated masking of the NLS is expected to have the
additional consequence of affecting APC1 association via this region as well.
Steady state localization of Apoptin is controlled by NES and NLS sequences that
must be coupled either intra- or intermolecularly to function in a cell type-specific
fashion.  Nuclear-cytoplasmic shuttling activity originating from the coupled activity of
these localization sequences is surprisingly critical for most Apoptin activities including
regulated localization behavior, APC/C association, and induction of apoptosis.  This
shuttling activity occurs in both normal and transformed cells and allows for the rapid
translocation of protein from one sub-cellular compartment to another.  The smaller
shuttling pool of Apoptin in primary cell types may involve stochastic conformational
changes in a sub-population of Apoptin molecules.  It is not likely that shuttling in
primary cell types has a definitive role to play in cytoplasmic retention or Apoptin
inactivity.  By contrast, the shuttling pool of Apoptin is much larger in transformed cell
types as indicated by rapid and complete nuclear exclusion in import blocking
experiments (Chapter II), indicating the vast majority of Apoptin is mobile.  Consistent
with this idea, Apoptin in transformed cells is readily immunoprecipitated as opposed to
in primary cells where it is mostly insoluble.
Apoptin localization sequences have evolved as overlapping protein-protein
interaction domains (Figure 4.1a), a strategy adopted by other compact and multifaceted
viral proteins (e.g. HIV-1 Rev, Chapter II).  It is possible that the activity of these
localization sequences is modulated by interaction with each respective protein
association as is the case with Rev.   Stimulation as well as inhibition of localization
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sequences has been observed in response to protein interaction (35, 83, 88, 141, 150,
180).  For example, activity at the NES may be positively or negatively responsive to the
degree of Apoptin multimerization.  Indeed, additional observations indicate that in
situations of constitutive Apoptin NES activity (through truncation or mutation of the
NLS region) dramatic increases in cytoplasmic aggregation are observed (data not
shown).  Behavior similar to this may take place for the APC/C interaction with the
Apoptin NLS region as well.  Association with the APC/C is sensitive to Apoptin
shuttling capability which suggests that continual access to the cytoplasm is necessary in
transformed cell types for this interaction to occur.  As many APC/C subunits are found
predominantly in the cytoplasm during interphase (80, 81, 170), including APC1
(unpublished observations), it is possible that Apoptin-APC1 association may first take
place there (see Figure 4.1c).  The equilibrium of shuttling may be shifted upon APC/C
binding and stimulate nuclear re-uptake, at which point the APC/C may be released, and
subsequent rounds of shuttling can take place.
Localization of Apoptin to the nucleus is required for induction of apoptosis in
transformed cells (Chapter I, Table 4.1).  Interestingly however, forcing Apoptin to the
nucleus of primary cell types by addition of supernumerary NLS sequences is not
sufficient to induce apoptosis (67).   Additionally, Apoptin mutations leading to
constitutive nuclear localization (e.g. point mutants of the NES) are also insufficient to
kill transformed cells.  In either case, however, normal Apoptin shuttling activity is
altered or prevented.  Thus, the requirements for Apoptin killing activity are more
complex than bulk nuclear localization of the protein.  Instead, it is likely that a critical
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steady state level of Apoptin protein is required in the nucleus resulting from a change in
shuttling equilibrium.  Continued cytoplasmic access and APC/C accessibility may
therefore be important requisites for Apoptin induced cell death.
It is clear that for certain capacities the specific Apoptin NLS region is
dispensable.  Functional replacement of the NLS with heterologous localization
sequences can be performed without consequence on cell type-specific localization.
However, the capacity for induction of apoptosis is lost, most likely due to interruption of
APC/C association.  By contrast, the function of the specific Apoptin NES region is
critical for regulated localization as well as apoptosis induction.  Cytoplasmic retention
and aggregation as well as export function are mediated by the activity of the Apoptin
NES domain.  These properties are responsible for maintenance of Apoptin in the
inactive state in primary cells and are negatively affected upon transformation.  In
contrast to other studies (discussed in Chapter II), this suggests that regulation of Apoptin
activity and localization between primary and transformed cell types involves modulation
of the N-terminal NES region.  It is possible that several potential phosphorylation events
proximal to the NES region may play a role in regulating functions, however the number
and placement of these sites is controversial (see Appendix).
In addition to shuttling activity, the induction of apoptosis in transformed cells by
Apoptin correlates with association with the APC/C (see Table 4.1).  The absence of
other subunits in preparative co-immunoprecipitation experiments with Apoptin suggests
that association with APC1 may either occur in free form separate from the remaining
subunits or simply reflect the greater IP efficiency observed with direct APC1 binding.
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Additional experiments (data not shown) indicate that Apoptin does co-purify with other
APC/C subunits including cdc27 (APC3) and cdc16 (APC6) albeit at relatively lower
levels than that of APC1.  This is interesting given that current data indicates that APC1
alone may exist at sub-stoichiometric levels relative to other subunits within the complex
(133).  FPLC analysis of Apoptin expressing cells demonstrates APC/C dissociation and
subunit degradation after 24 hours (Chapter III).   This indicates that APC/C dysfunction
occurs temporally prior to any appreciable levels of apoptosis.  G2/M cell cycle arrest,
however, is concurrent with APC/C dissociation and dysfunction suggesting that
inhibition of APC/C function by Apoptin is causative for both cell cycle arrest and
apoptosis.  Consistent with this idea, independent disruption of APC/C function by
ablation of APC1 mRNA results in G2/M arrest and apoptosis with similar temporal
progression and kinetics to that of Apoptin expression (Chapter III).  These data suggest
that interruption of APC1 function can lead to overall APC/C dysfunction as well as
indicate this as a plausible mechanism for the induction of apoptosis by Apoptin.
The molecular mechanism for APC/C disruption by Apoptin remains unclear.
Yeast genetic experiments have implicated APC1 in the assembly and regulation of the
cyclosome (see Chapter III discussion), however mechanistic data is not yet available.
APC1 is phosphorylated on greater than 40 residues where particular groups of residues
are modified in particular cell cycle stages suggesting this as a potential regulatory
mechanism for this subunit.  Additionally, it is known that cyclosome ubiquitination
function is affected by the status of phosphorylation on several subunits (including Cdc20
and Cdh1 activators) (76, 96).  One potential model would involve Apoptin affecting the
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phosphorylation status of APC1, which may alter APC/C activation, subunit assembly, or
complex stability.  Interestingly, the mechanism proposed for the Adenovirus E4orf4-
mediated inhibition of APC/CCdc20 involves recruitment of Protein Phosphatase-2A to the
APC/C and potential alteration of phosphorylation (95).
Recent studies suggest that the activity of the APC/C may be more complex than
originally believed; specifically, APC/C function is not merely restricted to anaphase and
kinetochore signaling.  Rather, there are at least two major versions of the complex: the
anaphase version of the APC/C exists in a form bound to the activator cdc20
(APC/CCcdc20), which is necessary for coordination of aforementioned mitotic events,
whereas another less understood complex exists mainly in G1 that binds to the activator
Cdh1 (APC/CCdh1) (reviewed in (134)).  Complete exit from mitosis is facilitated by
APC/Ccdc20-dependent destruction of Cyclin B, which begins in metaphase and continues
throughout anaphase while sister chromatids separate and migrate to the spindle poles.
Studies in Drosophila have shown that Cyclin B destruction occurs spatially in a wave
emanating from APC/C activity at the centrosomes, proceeding down the spindles, and
eventually arriving at the cell equator (81). In most cell types this destruction is
concurrent with the degradation of the cdc20 activator as well, which is replaced by the
cdh1 G1 activator protein for the APC/C.  APC/Ccdh1 localized to the centrosome can
presumably diffuse outward and catalyze the ubiquitination of residual Cyclin B in the
cytosol (80, 143). APC/Ccdh1 activity is maintained throughout G1 and functions primarily
to keep levels of mitotic cyclins low.  Despite this activity, Cyclin A levels eventually
rise in preparation for S-phase entry.  Recent studies indicate that APC/Ccdh1
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autonomously regulates itself in G1, allowing for inactivation when all substrates have
been destroyed.  Inactivation allows for the accumulation of Cyclin A effectively
coupling mitotic activity to G1 inactivation (145).
 In addition to autoregulatory activity in G1, the APC/C has also been implicated
in the direct regulation of S-phase entry.  Skp2 and its cofactor Cks1 are substrate-
targeting subunits of the E3 SCF ubiquitin ligase complex that regulates S-phase entry by
ubiquitination and subsequent degradation of the p21 and p27 CKIs.  This allows the
release of E2F from pRb and gene activation leading to G1/S transition.  APC/Ccdh1 has
recently been found to ubiquitinate and target for destruction both Skp2 and Cks1,
effectively inhibiting SCF function, preventing unscheduled entry into S-phase and
further maintaining the G1 state.  Inactivation of APC/Ccdh1 either by expression of non-
degradable forms of Skp2 or ablation of Cdh1 by RNA interference induces premature
entry into S phase (13, 14, 184).  Collectively, these studies suggest that the APC/C, in
addition to controlling mitosis, may represent an autonomous master regulator of the
metazoan cell cycle.
A role for the viral manipulation of the APC/CCdh1 complex is now becoming
evident.  Studies of CMV have suggested that this virus may act on the Cdh1-activated
APC/C specifically in G1 resulting in a release of APC/C-dependent SCF inhibition and
entry into S-phase (188).  This reveals a novel mechanism for the forced induction of S-
phase by a virus and reinforces the idea that the APC/C could represent a convergently
evolved nodal target of many viruses to manipulate the cell cycle at various stages.
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Whether Apoptin inhibition of the APC/C is restricted to the mitotic complex or involves
G1 APC/C modulation remains unclear.
Recent studies have succeeded in producing low-resolution structural maps of the
yeast and mammalian APC/C complexes using cryo-electron microscopy (62, 133).  As
mentioned before, it appears that APC1 exists in either sub-stoichiometric levels relative
to all other subunits or may exist in only certain APC/C complexes.  Studies in drosophila
have indicated that several distinct APC/C complexes may exist in the cell in addition to
the cdc20 and cdh1 activated forms (81).  The cyclosome, like many other large multi-
subunit complexes in the cell, may also be regulated at the level of subunit composition
where each sub-complex may have a distinct site of action and/or substrate specificity.  It
is possible that Apoptin may act on only those APC/C complexes which possess an APC1
subunit and have specific ubiquitination functions aside from, or in addition to, anaphase
progression.  Consistent with this, Apoptin arrested cells do not present typical metaphase
chromosomes expected for inhibition of only the mitotic checkpoint functions of the
APC/C.  Instead what is observed are cells arrested with intact nuclear membranes that
rapidly exhibit apoptotic morphology (data not shown).  Surprisingly, this somewhat
unexpected phenotype is also what has been observed for mutation of certain proteins
that modulate APC/C activity upstream in late G2 and early mitosis (104).  It is well
established that mitotic A-type cyclins and the kinase Nek2A are degraded during
prometaphase prior to chromatin condensation in an APCCdc20-dependent manner,
indicating that an APC/C is already active early in mitosis (43, 47, 61, 69, 156).  These
data have spawned suggestions that the APC/CCdc20 (or distinct sub-complexes) may also
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promote a novel late G2 checkpoint that can arrest cells before entering mitosis.  Thus, it
is clear that with the wide array of phenotypes observed by modulation of many different
APC/C effectors that cyclosome functions are diverse and numerous with respect to the
cell cycle.  Apoptin interaction with one or several of these complexes is expected to
result in unique multifaceted phenotypes beyond simple metaphase arrest.
Recent structural analysis of the APC/C has indicated that it may also operate as a
multimer.  Native gel analysis of purified APC/C from yeast reveals at least two
differently migrating forms that correlate with monomeric and dimeric species of the
complex (133).  The dimeric species has been shown to harbor ubiquitination
processivity in vast excess of that of the monomeric form suggesting that this may be the
predominant species of APC/C in vivo.  Consistent with these observations, close
inspection of the FPLC profile in Chapter III, Figure 3.4c also indicates that the APC/C
peaks at two migration points which could correlate to these monomeric and dimeric
forms.  This raises the interesting possibility that Apoptin could act on the APC/C by
preventing formation of processive dimers.  The effects of this type of activity on
cyclosome complex stability or cell cycle have yet to be determined.  Interestingly, it has
been suggested that the sub-stoichiometric levels of APC1 may also reflect that only one
of these subunits may be present for each APC/C dimer (133).    In this case APC1 could
serve to nucleate cyclosome dimers and/or bridge them together, lending credence to why
Apoptin should have evolved to target APC1 over other subunits.
Increasing evidence is favoring the idea that a block in APC/C function,
particularly in mitosis, leads to apoptosis independently of the actions of p53 (Figure 4.2
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and see discussion Chapter III).  Drug targeting of those activating stimuli upstream of
the APC/C, including the use of MIAs, induces G2/M cell cycle arrest and apoptosis in
the absence of p53 (118).  Likewise, newer drugs that block the actions of the proteasome
downstream of APC/C function also induce G2/M arrest and apoptosis regardless of p53
status (3-5).  Studies have shown that apoptotic signaling from mitotically arrested cells
involves stabilization of the BH3-only protein Bim (103, 118, 142).  Interestingly, some
cancers that have acquired resistance to MIAs show a lack of Bim stabilization but can be
re-sensitized by treatment with proteasome inhibitors such as Bortezomib that block
active Bim degradation (164).   These two classes of drug have been shown to act
synergistically when used in concert, supporting a method of action involving the same
pathway.   Given the similarities in G2/M arrest, p53-independence, and function of the
APC/C, it is likely that the killing action of Apoptin involves this same pathway as well
(see Chapter III).  These studies of Apoptin suggest that the APC/C is a nodal point in the
regulation of cell cycle and apoptosis and raise the insightful possibility that drug
targeting of the APC/C itself may prove to be effective for the selective killing of
transformed cells.
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Perspectives
Most organisms have been found to occupy a particular niche in which co-
evolution has occurred with one or many other organisms.  Viruses are no exception:
transformed cells can also be viewed as a reservoir for the evolution of certain viral
behaviors or protein activities.  In this regard, those viruses that have selected for
activities that are specific to cancerous cells can exploit beneficial aspects of
transformation at the cellular level.   Targeting of the APC/C by viruses including CAV,
HIV, CMV, HTLV and Adenovirus represents a newfound field deserving much
attention (73).  The convergent evolution of these viruses to target this cellular complex
suggests that there is an evolutionary advantage to be gained in doing so (see Figure 4.2).
The role of the APC/C is now being understood to be global in the regulation of many
aspects of the cell cycle, and several possible advantages can be envisioned through viral
manipulation of one or various forms of this complex.  It is possible that one strategy of
these viruses is to simultaneously stimulate S phase and block mitotic functions through
inhibition of both the Cdc20 and Cdh1 activated forms of the cyclosome.  With a minimal
amount of protein-protein interaction the virus could achieve a situation of unabated
genome replication while at the same time increasing the concentration of viral genomes
(and resultant progeny) by blocking cell division.  Alternatively, targeting of individual
forms of the APC/C has also been observed.  For example, CMV manipulation of Cdh1
activator in G1 results in activation of this APC/C and selective progression of S phase
independently of the mitotic complex.  Evidence also suggests that positive APC/C
regulation can occur in response to different proteins produced by these viruses.  In the
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case of HTLV-1, coordinated manipulation of the cdc20 activator protein results in rapid
progression of mitosis.
It is evident from clinical trials involving Bortezomib and Gleevec that the
development of drugs based on the inhibition of specific protein activities holds the
potential for far greater specificity and minimal collateral effects.   It is possible that
targeted inhibition of the APC/C may result in tumor cell killing with higher specificity
than that of the current drugs that target peripheral areas of APC/C regulation.  Specific
transformed cell targeting of the cyclosome by Apoptin is achieved through differential
localization, which is not readily available for a small molecule inhibitor.  However,
recent studies indicate that the development of many cancers involves the aberrant
expression of APC/C subunits and/or downregulation or mutation of endogenous APC/C
inhibitors (18, 132, 159, 160, 183).  Increased activity of the APC/C in transformed cell
types coupled with innate cellular sensitivity to the regulation and levels of this complex
could provide a large dosage-dependent difference for drug inhibition of normal versus
transformed cell APC/C.
Alternatively, it is possible that the essential nature of the APC/C and its functions
will result in a global inability to inhibit this complex in any situation.  Experiments must
be performed to address the therapeutic efficacy of differential inhibition of the complex
between normal and cancerous cells.  Quantification of primary and transformed cell
death following modulation of endogenous APC/C inhibitors may provide clues to
whether treatment using this complex is possible.  Additionally, the exact nature of
interaction of Apoptin with the various potential species of APC/C is unknown.  If one or
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more of these distinct complexes is found to differ in its activity, abundance, or subunit
composition between normal and transformed cells it might be possible to specifically
target such species for inhibition while leaving others undisturbed.  Future detailed
investigation of the APC/C in its various forms and functions throughout the cell cycle
will be integral to these endeavors.
Continued study of Apoptin as well as of other viral proteins that possess unique
properties in transformed cells holds the promise of identifying many novel targets that
may be of use in treating cancer.  The availability of such candidates, coupled with
evolving target-based drug development techniques have hope of providing anti-cancer
drugs similar to Gleevec, but with usefulness in treating a broad range of cancers
specifically and effectively.
134
Figure 4.1. Multifunctional localization signals mediate the cell type-specific
localization of Apoptin.  (A) Schematic diagram of Apoptin’s localization signals and
overlapping protein interaction domains.  (B) A model for the cell type-specific
localization of Apoptin.  In primary cells, Apoptin favors an NES dominant conformation
and aggregates by virtue of multimerization capacities present in the same domain.  In
transformed cells, Apoptin favors an NLS dominant conformation, possibly via
unmasking of the C-terminus (177), allowing for higher steady state levels of nuclear
protein.  (C) A model for the transformed cell-specific killing activity of Apoptin.  In
transformed cells, Apoptin shuttling is shifted toward nuclear accumulation.  The
localization of many APC/C subunits is predominantly cytoplasmic outside of mitosis;
Apoptin may either transport APC/C subunits from the cytoplasm to the nucleus, or
associate with APC/C subunits already present in the nucleus.  Apoptin-mediated
recruitment of APC/C into PML nuclear bodies in transformed cells leads to inactivation
of APC/C function and subsequent induction of G2/M arrest and apoptosis.
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Figure 4.2. Inhibition of the mitotic checkpoint leads to G2/M arrest and apoptosis
independently of p53.  Several promising cancer therapeutics target critical players in
the establishment of mitotic checkpoint control.  These various inhibitors have been
shown to induce G2/M cell cycle arrest followed by the induction of apoptosis in a
manner independent of the p53 tumor suppressor.  At the center of these activities is the
APC/C whose function may mediate the effects of microtubule inhibiting agents (MIA’s)
and possibly inhibitors of the 26S proteasome as well. The APC/C is beginning to be
understood as a critical node in the overall regulation of the cell cycle.  Several viral
proteins including Adenovirus e4orf4 protein and the CAV protein Apoptin are known to
induce G2/M arrest and have been shown to do so via inhibition of the APC/C.  These
viral proteins may inhibit both of the two known forms of the APC/C, which differ by
either the cdc20 or cdh1 activators. Effects observed with such viral inhibitors may
involve a common pathway leading to the induction of apoptosis.
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Table 4.1 Apoptin Mutants and Phenotypes. Various Apoptin mutations generated
throughout this study are listed with known localization, protein association, and
apoptotic phenotypes.  Those phenotypes not determined (N/D) are notated where
relevant.
A
p
o
p
ti
n
 M
u
ta
n
ts
 a
n
d
 P
h
e
n
o
ty
p
e
s
M
u
ta
n
t
Lo
ca
liz
at
io
n
Pr
im
ar
y 
ce
ll
Lo
ca
liz
at
io
n
Tr
an
sf
o
rm
ed
 C
el
l
S
h
u
tt
lin
g
A
ct
iv
it
y 
 
M
u
lt
im
er
iz
at
io
n
A
PC
1
A
ss
o
ci
at
io
n
A
p
o
p
to
ti
c 
A
ct
iv
it
y 
Tr
an
sf
o
rm
ed
 C
el
l
A
p
o
p
to
ti
c 
A
ct
iv
it
y 
Pr
im
ar
y 
C
el
l
G
FP
-w
tA
p
cy
to
p
la
sm
n
u
cl
eu
s
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
Fl
ag
-w
tA
p
cy
to
p
la
sm
n
u
cl
eu
s
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
Fl
ag
/G
FP
-A
p
(4
2
-8
8
)
cy
to
./
n
u
c.
cy
to
./
n
u
c.
-
-
-
-
-
Fl
ag
/G
FP
-A
p
(1
-4
8
)
cy
to
p
la
sm
cy
to
p
la
sm
-
+
+
+
+
+
+
-
-
-
Fl
ag
/G
FP
-A
p
(1
-8
8
)
cy
to
p
la
sm
cy
to
p
la
sm
-
+
+
+
+
+
-
-
-
Fl
ag
/G
FP
-A
p
(4
2
-1
2
1
)
n
u
cl
eu
s
n
u
cl
eu
s
-
-
+
*
+
/-
-
Fl
ag
/G
FP
-A
p
(8
2
-1
2
1
)
n
u
cl
eu
s
n
u
cl
eu
s
-
-
+
+
+
*
+
-
Fl
ag
/G
FP
-A
p
-p
m
N
E
S
n
u
cl
eu
s
n
u
cl
eu
s
-
+
+
+
+
+
-
-
d
sR
ed
/G
FP
-A
p
-p
m
N
LS
cy
to
p
la
sm
cy
to
p
la
sm
N
/D
N
/D
-
-
-
G
FP
-p
m
N
LS
2
cy
to
p
la
sm
n
u
cl
eu
s>
cy
to
.
N
/D
N
/D
-
-
-
G
FP
-A
p
N
E
S
re
v
cy
to
./
n
u
c.
cy
to
./
n
u
c.
N
/D
-
N
/D
-
N
/D
G
FP
-A
p
N
LS
sv
4
0
cy
to
p
la
sm
n
u
cl
eu
s
N
/D
N
/D
-
-
-
Fl
ag
/G
FP
-A
p
(T
1
0
8
E
)
n
u
cl
eu
s
n
u
cl
eu
s
N
/D
+
+
+
+
+
N
/D
†+
+
+
+
+
+
+
+
+
+
+
+
+
Fl
ag
/G
FP
-A
p
(T
1
0
8
A
)
n
u
cl
eu
s
n
u
cl
eu
s
N
/D
+
+
+
+
+
+
+
+
+
+
+
+
+
+
+
-
Fl
ag
/G
FP
-A
p
(T
1
0
6
,1
0
7
,1
0
8
A
)
n
u
cl
eu
s
n
u
cl
eu
s
N
/D
+
+
+
+
+
+
+
+
+
+
-
-
Fl
ag
-A
p
(1
-1
0
2
)
N
/D
N
/D
N
/D
N
/D
-
N
/D
N
/D
Fl
ag
-A
p
(7
5
-9
9
)
N
/D
N
/D
N
/D
N
/D
-
N
/D
N
/D
Fl
ag
-A
p
(8
7
-1
1
1
)
N
/D
N
/D
N
/D
N
/D
-
N
/D
N
/D
Fl
ag
-A
p
(9
7
-1
2
1
)
N
/D
N
/D
N
/D
N
/D
-
N
/D
N
/D
Fl
ag
-A
p
(7
3
-1
2
1
)
N
/D
N
/D
N
/D
N
/D
+
+
+
N
/D
N
/D
Fl
ag
-A
p
(7
6
-1
2
1
)
N
/D
N
/D
N
/D
N
/D
+
+
+
+
N
/D
N
/D
G
FP
-A
p
(T
8
A
)
n
u
cl
eu
s
n
u
cl
eu
s
N
/D
N
/D
N
/D
N
/D
N
/D
G
FP
-A
p
(T
2
7
A
)
n
u
cl
eu
s
n
u
cl
eu
s
N
/D
N
/D
N
/D
N
/D
N
/D
G
FP
-A
p
(T
8
/2
7
A
)
n
u
cl
eu
s
n
u
cl
eu
s
N
/D
N
/D
N
/D
N
/D
N
/D
A
p
(1
-4
8
)-
G
FP
-A
p
(8
2
-1
2
1
)
n
u
cl
eu
s
n
u
cl
eu
s
N
/D
N
/D
N
/D
N
/D
N
/D
A
p
N
E
S
-G
FP
-A
p
(8
2
-1
2
1
)
n
u
cl
eu
s
n
u
cl
eu
s
N
/D
-
N
/D
N
/D
N
/D
A
p
N
E
S
-G
FP
cy
to
./
n
u
c.
cy
to
./
n
u
c.
N
/D
-
N
/D
N
/D
N
/D
D
en
o
te
d
 a
ct
iv
it
ie
s 
ar
e 
re
la
ti
ve
 t
o
 w
tA
p
*
 R
es
u
lt
s 
av
er
ag
ed
 f
ro
m
 G
FP
 a
n
d
 F
la
g
 f
u
si
o
n
 e
xp
er
im
en
ts
 (
se
e 
fo
o
tn
o
te
 2
, 
C
h
ap
te
r 
II
I)
  
 A
ct
u
al
 q
u
an
ti
fi
ca
ti
o
n
 i
s 
g
re
at
er
 t
h
an
 t
h
at
 s
h
o
w
n
 (
se
e 
A
p
p
en
d
ix
)
†Ta
bl
e 
4.
1
139
140
APPENDIX
ANALYSIS OF APOPTIN REGULATION BY PHOSPHORYLATION
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Introduction
Efforts to isolate the transformed cell-specific activity(ies) that act upon Apoptin
have been conducted throughout this study as well as in others, however, none have yet
been successful.  Current data indicates that the most likely candidate for this activity is
one that modulates phosphorylation (i.e. kinase or phosphatase).  The few studies that
have reported on investigation of such an activity have suggested the existence of a
transformed cell-specific kinase that potentially modifies Apoptin at the C-terminus (151,
193).  Specifically, phosphorylation of the single residue T108 has been suggested to take
place only in transformed cell types and is absent in primary cells.  This phosphorylation
has been proposed to activate nuclear entry as well as the apoptotic activity of Apoptin.
In the same studies, the ablation of phosphorylation at this site by mutagenesis of the
target threonine residue was shown to nullify any such activation and translocation.
During the execution of the work presented in the previous chapters, a significant
amount of time was devoted to verification and clarification of Apoptin cell type-specific
phosphorylation.  Efforts were made to dissect the specific functional consequences of
T108 phosphorylation on localization and apoptotic activity, however many of the results
obtained were contradictory to various aspects of the published literature.  Those results
that were in agreement with what has previously been reported remain open to
interpretation.  This section serves to introduce some of the unpublished findings
elucidated from these efforts and to illustrate areas of consistency and inconsistency from
previously published results.
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Materials and methods
Cells and adenoviruses.  H1299 and primary lung fibroblast cells (MRC-5) were
obtained from ATCC and maintained in Dulbecco’s modified Eagle’s medium
supplemented with 10% fetal bovine serum plus 10 mg/ml streptomycin and 10 U/ml
penicillin (Sigma) at 37°C under 5% CO2 (95% air).
Ad-Apwt, Ad-Ap-pmNES, and Ad-LacZ were prepared as previously described
(Chapter II).  All cells were infected at approximately 80% confluence at an MOI of 35.
Adenovirus was added to cells in a minimal volume of culture media and gently agitated
at 37°C under 5% CO2 for 1 h.  Following infection, culture media was added and cells
were incubated for indicated times.
Plasmid constructions. GFP- and Flag-Apoptin phosphorylation site point mutations
were generated by PCR-mediated site directed mutagenesis of indicated residues
followed by cloning into either the pEGFP-C1 (Clontech) or p3XFLAG-myc-CMV-26
(Sigma) vectors via engineered EcoRI and BamHI restriction sites.  All constructs were
confirmed by DNA sequencing.
Metabolic labeling and two-dimensional electrophoresis. Thirty-six hours following
infection with either Ad-Apwt, Ad-pmNES or Ad-LacZ virus, cells were washed in PBS
and placed into DMEM (10% FBS) without phosphate for 20 min.  Media was then
replaced with a minimal volume of phosphate lacking DMEM supplemented with
~1.5mCi 32P-orthophosphoric acid.  Cells were labeled for 2 hours, washed 3x in PBS,
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and harvested by scraping.  Cells were then lysed in RIPA buffer [150 mM NaCl, 1%
NP40, 0.5% Na deoxycholate, 0.1% SDS, 50 mM Tris pH8.0, 5mM EDTA, Complete
Mini tablet (Roche)] and subjected to immunoprecipitation (see below).
For two-dimensional electrophoresis, recovered immunoprecipitates were first
subjected to isoelectric focusing (pH range of 6.0-10.0) using a Zoom Runner system
(Invitrogen; see commercial protocol for details).  The second dimension was
accomplished via SDS-PAGE (gradient 6-15%) (Invitrogen).  Gels were dried, and
labeled protein was visualized by autoradiography.
Immunoprecipitations. Following 9,000 x g centrifugation for 30 min., supernatants
were incubated with 20 μl equilibrated EZview Red -Flag M2 affinity beads (Sigma) at
4°C for 4 h.  Beads were washed in RIPA buffer, and bound proteins were eluted in 1X
sample resuspension buffer (Invitrogen).
Apoptosis assays. For cell viability assays, H1299 and PFF cells transfected with Flag-
Apoptin phosphorylation site mutants were harvested, washed in PBS, and stained with
ViaCount reagent (Guava Technologies).  Viability was quantified using a Guava
Personal flow cytometer.  Data points were collected as percent cell viability per 5000
events.  For H1299 cells, data was graphed as fold X increase of wild type activity, where
Apwt was set to 1.  For MRC-5 cells, data was graphed as percent Apoptosis.
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Results
Apoptin phosphorylation state differs between primary and transformed cells.
Previous reports have suggested that Apoptin may be controlled by phosphorylation (151,
193).  Differences between the primary or transformed cell phosphorylation status of
Apoptin could represent a potential regulatory mechanism. Therefore, the
phosphorylation status of Apoptin between primary and transformed cells was examined
by metabolic 32P-ortho-phosphate labeling.  H1299 and MRC-5 primary lung fibroblast
cells were infected with either Ad-Apwt or Ad-LacZ virus and after 36 hours were
labeled with 32P-orthophosphoric acid.  Cell extracts were then subjected to Flag
immunoprecipitation followed by SDS-PAGE and autoradiography to visualize labeled
Apoptin protein. Contrary to previous reports, Figure 5.1a shows that compared to Ad-
LacZ infected cells, Apoptin is robustly phosphorylated in primary as well as transformed
cells.  Similar results were obtained using normal PFF cells (data not shown).
The lack of any appreciable difference in phosphorylation status between normal
and transformed cells prompted examination of the patterns of Apoptin phosphorylation
in these two cell types.   To address this, H1299 and MRC-5 cells were again infected
with Ad-Apwt virus and subjected to metabolic labeling and immunoprecipitation as
before.  Two-dimensional electrophoresis was then performed on the resultant IP material
by first dimension isoelectric focusing followed by second dimension gradient SDS-
PAGE.  Proteins were then visualized by autoradiography as before.  Figure 5.1b shows
that Apoptin phosphorylation status differs greatly between normal and transformed cell
types as the degree of phosphorylation is more extensive in transformed cells.
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Additionally these results suggest that at least 4 separate phosphorylation events occur in
H1299 cells as evidenced by labeled foci separated by the second dimension.  Together
these results suggest that although Apoptin is phosphorylated in both normal and
transformed cell types, the residues that are phosphorylated differ between these two cell
types.
T108 region modulates Apoptin behavior. Previous studies have suggested that T108
phosphorylation specifically activates Apoptin.  To verify such observations, several
point mutants were constructed in both GFP and Flag vector backgrounds and are
detailed in Figure 5.2a.  As a test for the necessity of T108 phosphorylation, this site was
substituted with alanine.  A T108E mutation was also constructed similarly to previous
reports that suggest this mutation to simulate phosphorylation (193).  T108 is part of a
triplet of threonine residues within the C-terminus of Apoptin.  Given the evidence of
Figure 5.1b for multiple phosphorylations, a mutant was also constructed where
threonines 106, 107 and 108 were mutated to alanine.
Surprisingly, Figure 5.2b shows that expression of GFP-Apoptin phosphorylation
mutants into both MRC-5 and H1299 cells results in nuclear localization in all cases, as
compared to GFP-Apwt, which maintains the expected cell type-specific localization
behavior.
To assess the apoptotic potential of these proteins, Flag epitope tagged versions of
each mutant were transiently expressed in both H1299 and MRC-5 cells and after 72
hours, cell viability was quantified by flow cytometry.  Figure 5.2c shows that relative to
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Flag-Apwt, the Flag-Ap(T108E) mutation had approximately 7-fold greater apoptotic
activity in H1299 cells.  Flag-Ap(T106,107,108A) showed negligible activity, however,
Flag-(T108A) expression yielded levels of apoptosis approximately 2-fold higher than
that of Flag-Apwt.  These results indicate that mutation of T108 to either alanine or
glutamic acid is able to increase the apoptotic activity of Apoptin, especially in the case
of the latter.
As expected, Flag-Apwt showed negligible apoptotic activity in MRC-5 cells.
Similarly, the Flag-Ap(T108A) and Flag-Ap(T106,107,108A) mutants showed no
appreciable amount of apoptosis, despite the nuclear localization observed in Figure 5.2b.
Interestingly, the Flag-Ap(T108E) mutant showed a robust ability to induce apoptosis in
MRC-5 cells.
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Discussion
  The results of Figure 5.1 indicate that, in contrast to previous reports, kinase
activity(ies) responsible for Apoptin phosphorylation is not restricted to transformed cells
but occurs in normal cells as well.  These results also indicate that T108 is not the only
residue that is phosphorylated.  Apoptin may have as many as four phosphorylated
residues in transformed cells suggesting that alternate phosphorylations may contribute to
(or control) the activity of Apoptin.  Several attempts to identify such residues by mass-
spectrometry were unsuccessful, possibly due to the labile nature of these
phosphorylations.  Additionally, T108 phosphorylation specifically was not observed in
these attempts.  Other groups have attempted to verify T108 phosphorylation in
transformed cells by metabolic labeling and mass-spectrometry and have also reported
inability to verify this modification (176).
Consistent with what has been reported, however, substitution of T108 does affect
the killing capacity of Apoptin.   Interestingly, modification of T108 to either alanine or
glutamic acid was able to increase apoptotic activity, however T108A appears to have
retained cell-type specificity and was hyperactive to a lesser degree than was T108E.
Given the unpredictable nature of amino acid substitution, it is formally possible that the
T108E mutation in this case is acting as a loss of function mutant as apposed to the
anticipated phosphorylation site “mimic”.  Thus, given the data obtained from the T108A
mutant, it is possible that blocking phosphorylation at this site has activating potential.
Additionally, activation may also be related to conformational changes within this area in
response to the amino acid substitutions.  Introduction of charged residues such as
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glutamic acid into this region may alter the local geometries of the C-terminus or may
have protein-wide consequences.  This would be understandable as Apoptin is a small
protein with multiple overlapping functional regions.  Through these studies it is at least
clear that the nature of Apoptin phosphorylation and its consequences on protein function
are more complex than is suggested in the literature.
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Figure 5.1. Apoptin phosphorylation status differs between primary and
transformed cells. (A) 24 hours after introduction of either LacZ or wtAp adenoviruses
(or mock infected samples) Apoptin phosphorylation status was monitored in MRC-5 and
H1299 cells by metabolic 32P ortho-phosphate labeling for 3 hours followed by
immunoprecipitation of Apoptin using a-Flag affinity resin.  Immunoprecipitate was
separated by SDS-PAGE and phosphorylated proteins were visualized by
autoradiography.  Apoptin protein levels were monitored by -Flag western blot of whole
cell extracts prepared in parallel.  (B) 2-dimentional gel electrophoresis of 32P ortho-
phosphate labeled Apoptin protein recovered from (A) in either H1299 or MRC-5 cells.
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Figure 5.2.  Mutation of putative C-terminal phosphorylation region of Apoptin
modulates sub-cellular localization and killing activity. (A) Schematic of Apwt vs.
Apoptin phosphoylation site mutations.  (B) Sub-cellular localization of GFP-Apoptin
phosphorylation site mutants compared to GFP-Apwt in both H1299 and MRC-5 cells.
(C) Analysis of apoptotic capacity of Flag-Apoptin phosphorylation site mutants in either
H1299 or MRC-5 cells.  H1299 cell viability is shown as fold increase over Apwt activity
(which is normalized to 1).  MRC-5 cell viability is shown as % apoptosis.
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